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Abstract
Mycobacterium tuberculosis (Mtb) is a serious health issue arising from the increasing
incidence of multi-drug resistant (MDR-TB) strains that are becoming more prevalent in high-risk
countries, especially here in the Texas/Mexico border. Confirmed cases and outbreaks in schools
and hospitals are more frequent in this region due to the high-volume pedestrian traffic between
the two cities, and the lack of a modernized health system in Mexico. Identification of new Mtb
metabolic pathways for development of novel antitubercular drugs is urgently needed. The goal of
this current work investigates two Mtb fatty acyl-CoA ligase enzymes’ (FadD17A1 and
FadD19A1) to explore whether removal of these genes would affect Mtb’s ability to grow on
cholesterol using M. smegmatis as a model. It has been previously shown that FadD19A1 is
essential for degradation of steroids with C24 branched side-chains in vivo [1]. Our initial
hypothesis was that the utilization of host cholesterol reshapes Mtb’s metabolism as an adaptive
mechanism for survival in macrophages and that these two acyl-CoA ligases (FadD17A1 and
FadD19A1) play an essential role in the cholesterol degradation process. We have been able to
show that slight redundancy exists in these enzymes’ ability to turn over all acid intermediates of
cholestenone tested in vitro including 23,24-bisnor-chol-1,4-dienic acid (C22), (23,24-bisnor-5αcholenic acid-3-one (C22), 5-cholenic acid-3β-ol (C24), 4-cholenic acid-3β-ol (C24), as well as
25-R and 25-S isomers of 3-oxo-4-cholestenoic acid (C27). The 25-S isomer of 3-oxo-4cholestenoic acid (C27) seems to be the best substrate for activity with FadD19A1, while 4cholenic acid-3β-ol (C24) appears to be the best substrate for FadD17A1. We have also been able
to show that both FadD17A1 and FadD19A1 can act on C5-C18 saturated fatty acids but have a
stronger affinity for mid-chain saturated fatty acids, and increased activity with longer chain fatty
acids can be accomplished by introducing one and two degrees of unsaturation. Our next goal was
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to evaluate the effect of removal of both acyl-CoA ligase enzymes’ and determine the effect on
growth utilizing various media, as well as metabolic profiling of mutant strains. A slight growth
deficiency was obtained with our mutant strains after the log phase only when utilizing a more
complex media with multiple carbon sources. These data support the initial hypothesis of this study
which predicts important roles for the FadDs in the reshaping of Mtb’s metabolism from glucose
to cholesterol. Profiling data demonstrated significant accumulation of cholestenoic acid (4CHOL) in mutant strains deficient in fadD19A2 as well as 4-CHOL-26OOMe and 4-CHOL26OOEt in all mutant strains deficient in any combination of the FadD enzymes. Detection of
methylated C and D ring metabolite CD-26OOMe was the only accumulated CD ring metabolite
detected in the fadD mutant strains compared to wt. Accumulation of 4-cholenic acid (4-C) and
detection of 23,24-Bisnor-4-Cholenic acid (4-BNC) was only possible when fadD mutant strains
were also deficient for expression of KstD. Detection of methylated acid intermediates including
4-CHOL-26OOMe, 4-C-24OOMe, and 4-BNC-22OOMe were now also detectable and higher in
mutant strains, deficient for expression of KstD as well, compared to wt. As expected, C and D
ring intermediates among these kstd/fadD mutants was lower including CD-26OOMe, CD24OOMe and CD-22OOMe compared to wt. This data indicates esterification mechanisms as well
as subsequent opening of rings A and B as compensatory mechanisms when side-chain degradation
is blocked. Use of a propionate reporter construct allowed us to visualize decreased levels of
propionate among the mutant strains when grown in the presence of cholest-4-en-3-one, supporting
the compensatory mechanisms above. Acid-fast staining of our mutant strains illustrated that all
our mutants, except for the ΔfadD19A2 and ΔfadD19A2/fadD19B1 mutants, appear to have lost
their acid-fast phenotype. Together, our data demonstrate that targeting of enzymes acting on the
side chain degradation of cholesterol will not lead to production of toxic intermediates and
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bacteriostatic effects, but will instead lead to altered endogenous propionate production and
subsequent altered lipid composition of the cell wall. These results provide promising avenues for
continued investigation of ligase enzymes in this pathway for development of novel therapeutics
capable of targeting the synthesis of many virulence lipids that could be used to help control the
proliferation of drug resistant tuberculosis.

ix

Table of Contents
Acknowledgements………………………………………………………………………………..v
Abstract…………………………………………………………………………..........................vii
Table of Contents………………………………………………………………………………….x
List of figures…………………………………………………………………………………….xii
List of tables……………………………………………………………………………………..xiv
Chapter 1: Background and Significance…………………………………………………….……1
1.1 Mycobacterium tuberculosis structure and history……………………………….……1
1.2 Epidemiology of TB infection and at-risk patients…………………………………….2
1.3 Multidrug resistance prevalence…………………………………………………….…2
1.4 Cholesterol metabolism and importance in pathogenesis……………………………...4
1.5 Mtb FadD acyl-CoA ligases and their role in cholesterol/fatty acids degradation.........10
1.6 Analysis of M. smegmatis as a model for Mtb and comparison of acyl-CoA ligases
between the two organisms..........................................................................................14
1.7 Significance..................................................................................................................20
1.8 Specific aims and hypothesis………………………………………………….……...21
Chapter 2: Elucidating enzymatic activities in vitro using recombinant Mtb acyl-CoA ligases
FadD17A1 and FadD19A1….......………………………………………………….………….…23
2.1 Methods………………………………………………………………………............23
2.2 Results………………………………………………………………………..............36
2.3 Discussion………………………………………………………………………........45

x

Chapter 3: Growth, metabolic profiling and activity-based metabolomics profiling of M.
smegmatis DfadD17A2, DfadD19A2, and DfadD19B1 mutant strains in combination with DkstD
utilizing various media……………………………………………………………………….......49
3.1 Methods…………………………………...…………………………………….........49
3.2 Results…………………………………………………………...……………...........58
3.3 Discussion……………………………………………………………………...….....70
Chapter 4: Growth and metabolic profiling of M. smegmatis fadD17A2, fadD19A2and fadD19B1
mutant strains utilizing various media……………………………………………....................…74
4.1 Methods…………………………………………....................…................................74
4.2 Results…………………………………………....................…..................................78
4.3 Discussion…………………………………………....................…............................88
Chapter 5: Overview and final conclusions…………………………………………....................94
References…………………………………………....................………………………………101
Appendix…………………………………………....................………………………………..112
Vita…………………………………………....................……………………………………...115

xi

List of Figures
Fig 1 Schematic of granuloma structure, characteristic of Mtb infection..........................................5
Fig 2 Initial proposed cholesterol side-chain degradation pathway with hypothetic
catabolic intermediates.………………………………....................…..................................9
Fig 3 Differences in mechanism of fatty acid processing, mediated by fatty acid CoA ligases
and fatty acid AMP ligases…….………………………………....................…..................12
Fig 4 Genomic organization of fadD17A1 and fadD19A1 and surrounding genes of Mtb H37Rv..13
Fig 5 FadD17A1 and FadD17A2 conservation analysis………………………………………….17
Fig 6 FadD19A1, FadD19A2 and FadD19B1 conservation analysis…………………………......18
Fig 7 Sequence alignment among FadD homologues………………………………………….....19
Fig 8 pYUB28bLIC circular plasmid design for expression of His-tagged FadD17A1 in
M. smegmatis and linear map illustrating tag, operators, and ribosomal binding site...........25
Fig 9 pYUB-28bLIC-Strep circular plasmid design for expression of Strep-tagged
FadD19A1 (Mtb) in M. smegmatis and linear map illustrating tag, operators, and
ribosomal binding site........ …….....................................……………………………........27
Fig 10 pYUB-28bLIC-Strep circular plasmid design for expression of Strep-tagged
FadD19B1 (M. smeg) in M. smegmatis and linear map illustrating tag, operators, and
ribosomal binding site. ………………………………………….........…………………..28
Fig 11 Illustration describing expression and activity testing of purified recombinant
FadD19A1, FadD17A1 and FadD19B1………………………………..............................33
Fig 12 SDS-PAGE analysis of purified Mtb FadD17A1, FadD19A1, and M. smegmatis
FadD19B1………………………………………….............................................…..........37
Fig 13 Substrate preference of steroids for FadD17A, FadD19A1 and FadD19B1.........................40
Fig 14 Elucidation of substrate preference of steroids with purified FadD19A1............................42
Fig 15 Substrate preference of fatty acids for FadD17A1 and FadD19A1......................................44
Fig 16 Primer design and PCR screening to confirm removal of fadD19A2 in previously
obtained mutant strains in M. smegmatis.............................................................................60
Fig 17 Growth of Δkstd mutant strains in M. smegmatis with 7H9, 0.2% glycerol (v/v) and
7H9, 0.2% glycerol (v/v), 1 mM cholest-4-en-3-one…..……………………....………….61
xii

Fig 18 Metabolic profiling of Δkstd mutant strains in M. smegmatis with 7H9, 1 mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 345, 373 and 415.........................62
Fig 19 Metabolic profiling of Δkstd mutant strains in M. smegmatis with 7H9, 1 mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 359, 387 and 429........................64
Fig 20 Metabolic profiling of Δkstd mutant strains in M. smegmatis with 7H9, 1 mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 443, and 395...............................65
Fig 21 Metabolic profiling of Δkstd mutant strains in M. smegmatis with 7H9, 1 mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 325, and 353...............................66
Fig 22 Activity-based metabolic profiling assay of Δkstd/fadD17A2 mutant strain with
FadD17A1, FadD19A1, or co-incubation with both............................................................67
Fig 23 Steroid activity-based metabolic profiling assay of Δkstd/fadD17A2 mutant strain
with FadD17A1, FadD19A1, or co-incubation with both....................................................69
Fig 24 Growth of mutant strains in M. smegmatis with 7H9, 0.2% glycerol (v/v), 1mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol (v/v) ……….…………..……………….......79
Fig 25 Growth of mutant strains in M. smegmatis with 7H9, 0.2% glycerol (v/v), 0.2%
glucose (v/v), 05% Tween-80 (v/v), 0.45% ethanol (v/v), 0.5 mM
cholest-4-en-3-one..............................................................................................................81
Fig 26 Metabolic profiling of mutant strains in M. smegmatis with 7H9, 0.2% glycerol,
1 mM cholest-4-en-3-one, 0.5% Tyloxapol/ethanol for [M+H]+ 385, 401
and 415................................................................................................................................83
Fig 27 Metabolic profiling of mutant strains in M. smegmatis with 7H9, 0.2% glycerol,
1 mM cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 429, 443
and 395................................................................................................................................84
Fig 28 Luciferase reads of mutant strains in M. smegmatis transformed with
pMV261zeo/prpR-FFlucRT grown with glycerol, acetate and propionate..........................86
Fig 29 Luciferase reads of mutant strains in M. smegmatis transformed with
pMV261zeo/prpR-FFlucRT grown with oleic acid, 5-cholenic and
cholest-4-en-3-one..............................................................................................................87
Fig 30 Ziehl-Neelsen staining of M. smegmatis wt and mutant strains DfadD17A2,
DfadD19A2, DfadD19A2/fadD19B1, DfadD17A2/fadD19A2 and
DfadD17A2/fadD19A2/fadD19B1.......................................................................................89
Fig 31 Modified cholesterol side-chain degradation pathway with compensatory mechanisms.....98

xiii

List of tables
Table 1 Identification of fatty acid CoA ligases (FACL) and fatty acid AMP ligases
(FAAL) between Mtb and M. smeg………………….......…....................….....................11
Table 2 Table of Mycobacterium models used for Mtb research.....................................................15
Table 3 Plasmid and primer design for expression of His/Strep-tagged FadD17A1,
FadD19A1 FadD19B1 in E. coli and/or M. smegmatis………...………………………...24
Table 4 Composition of reaction mixture for the reconstitution of enzymatic activity of
purified recombinant FadD17A1, FadD19A1, or FadD19B1............................................34
Table 5 Substrate preference for steroids and fatty acids of FadD17A1 and FadD19A1.................46
Table 6 Metabolites profiled during metabolic profiling assay for wt and mutant strains
in M. smegmatis …………...……………………....................….....................................54

xiv

Chapter 1: Background and Significance
1.1 Mycobacterium tuberculosis structure and history
Mycobacterium tuberculosis (Mtb) is a non-motile bacillus-shaped bacterium that is
characterized by its highly complex cell wall envelope, composed of mycolic acids which are long
chain α-alkyl and β-hydroxy fatty acids. The characteristic cell wall envelope significantly
contributes to the well-known low permeability of Mtb cells and their unique staining requirements
using Ziehl-Neelsen acid-fast stain [2, 3]. The bacilli, are typically 2-4 micrometers in length, and
are obligate aerobes as demonstrated by their preferred area of infection in the lungs. The
Mycobacterium genus has been proposed to have originated more than 150 million years in the
past [4]. Mtb has been found in the spine and skull of Egyptian mummies documented at more
than 5000 years of age [5]. The Mycobacterium genus is usually divided into two distinct groups
based on the constituent species’ rate of division; the slower growing species, such as Mtb,
Mycobacterium bovis, and Mycobacterium leprae belong to the pathogenic group responsible for
human tuberculosis (TB), bovine tuberculosis (BTB) and human leprosy respectively [2, 6]. The
faster growing species such as Mycobacterium smegmatis, in general, are opportunistic or nonpathogenic. Mtb has significantly impacted history and understanding of the pathogenesis of
tuberculosis began with the work of Théophile Laennec at the beginning of the 19th century.
Conceptual understanding of the etiological agent of TB infection was further advanced by the
demonstration of the transmissibility of Mtb infection by Jean-Antoine Villemin in 1865. This was
followed by the very important and well-known identification of the tubercle bacillus as the
etiologic agent by Robert Koch in 1882, for which he was eventually awarded the Nobel Prize in
Physiology and Medicine in 1905 [5, 7]. Clemens von Pirquet was responsible for developing the
tuberculin skin test in 1907 expediting rapid detection, and permitting earlier treatment, and three
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years later used the test to demonstrate latent tuberculosis infection in asymptomatic children [810].
1.2 Epidemiology of TB infection and at-risk patients
Mtb is contracted by inhalation of aerosols from an infected individual which can occur
through sneezing, coughing and even general conversing; and is currently affecting one-third of
the world’s population [11]. The WHO has reported that in 2016 there were 10.4 million new TB
cases globally, and 1.7 million resulting in fatalities, making it the 9th leading cause of death
worldwide [11]. Diagnosis of latent tuberculosis infection (LTBI) is an essential tool for assessing
the burden of TB for epidemiological studies because LTBI results in meaningful additions to the
pool of active TB cases as time passes and latent TB activates [12]. The tuberculin skin test (TST)
and interferon-gamma release assays (IGRAs) have been used as diagnostic tests for the detection
of LTBI [13, 14]. TB is especially dangerous to those patients with compromised immune systems,
such as HIV patients. Among the 1.7 million fatalities from 2016, 400,000 deaths were of people
who were HIV positive [11]. Today, TB is known to be one of the top killers of women both HIV
positive and negative [11].
1.3 Multidrug resistance prevalence
Current difficulties with treatment of human tuberculosis (TB) result from the increasing
incidence of rifampicin resistant (RR-TB) as well as multi-drug resistant (MDR-TB) strains that
are becoming more prevalent in high-risk countries. In 2016, 600,000 new cases involved RR-TB,
and of those, 490,000 cases involved MDR-TB; India, China, and the Russian Federation
accounted for almost half of these cases [11]. Current treatment for patients infected with active
TB includes a cocktail of drugs that are normally taken for at least 6 months to 1 year.
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One of the most common drugs used for treatment is isoniazid, which is a prodrug and
must be activated by a bacterial catalase-peroxidase enzyme that in Mtb is called KatG. KatG
forms an inhibitory complex that inhibits the NADH-dependent enoyl-ACP reductase (InhA) by
binding to nicotinamide adenine dinucleotide (NAD+ or NAD-) [15]. The adduct formation
resulting from the isoniazid/KatG complex inhibits the fatty acid synthase type II (FASII) enoylACP reductase InhA, resulting in long-chain fatty acid accumulation, inhibition of mycolic acid
biosynthesis and cell death [16, 17]. A range of radicals is produced by KatG activation of
isoniazid, including nitric oxide, which helps clear the infection [18, 19]. Mutations in S315T/M
in KatG, along with mutations in the promoter region of the inhA operon, are the most commonly
found mutations in M. tuberculosis, resulting in high levels of resistance to isoniazid [17, 20].
Rifampicin treats TB by acting as an inhibitor of the β-subunit of the RNA polymerase of Mtb
[21]. Rifampicin inhibits bacterial DNA-dependent RNA synthesis by inhibiting bacterial DNAdependent RNA polymerase. Rifampicin binds to RNA polymerase and blocks RNA synthesis by
physically preventing extension of RNA products beyond a length of 2-3 nucleotides [22].
Resistance to rifampicin is mediated by mutations in a small region of the rpoB gene (mutations
at codons 516, 526, and 531 in the cluster I region are the most frequent) [21, 22].
Multidrug-resistant TB (MDR-TB) is defined as being resistant to isoniazid and rifampicin
[23]. Extensively drug-resistant TB (XDR-TB) strains are grouped with MDR-TB, but additionally
carry resistance to any fluoroquinolone (levofloxacin, moxifloxacin, ofloxacin, gatifloxacin) and
any second-line (s-line) injectable antibiotics such as kanamycin, amikacin or capreomycin.
Extremely drug-resistant TB (XDR-TB) or totally drug-resistant TB (TDR-TB) have been used by
various authors to describe strains with more extensive patterns of resistance to all first-line drugs
including isoniazid, pyrazinamide, ethambutol, rifampicin/rifampin and rifabutin; as well as s-line
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drugs including kanamycin, amikacin, capreomycin, streptomycin, and fluoroquinolone drugs
(mentioned above) [24]. There is still debate, however, on these extreme resistant strains; due to
problems with the reliability and reproducibility of in vitro drug susceptibility testing for s-line
drugs, it is conventional that these strains are usually termed “resistant beyond XDR” [24, 25].
1.4 Cholesterol metabolism and importance in pathogenesis
Previous work focusing on finding alternate treatment strategies for MDR-TB [3, 23, 26,
27] has illustrated the particular importance of Mtb’s unique metabolic alterations in the harsh
environment of macrophages and other host cells where it proliferates. Once inside the
macrophage phagosome, the bacilli are faced with a nutrient-deficient environment and must
switch their metabolism to rely on lipids stored in lipid droplets as a primary carbon source (Figure
1) [28]. One of the hallmark signs of TB infection is the adaptation and formation of the granuloma
structure, which provides Mtb with a niche to evade the immune system for prolonged periods of
time [29-32]. Essentially, TB infection is initiated when bacilli are inhaled and phagocytosed by
alveolar macrophages. Proinflammatory responses will trigger infected cells to invade subtending
epithelium and lead to recruitment of monocytes from blood vessels. This process provides fresh
host cells as well as extensive neovascularization of the infection site characteristic of the
granuloma structure. The macrophages in the granuloma differentiate to form epithelioid cells,
multinucleate giant cells, and foam cells filled with lipid droplets which provide cholesterol as a
source of carbon. Lymphocytes, which indicate the onset of the immune response, are restricted
primarily to the peripheral area. The granuloma becomes further stratified by the formation of a
fibrous cuff of extracellular matrix (Figure 1). The progression toward disease is characterized by
the loss of vascularization, increased necrosis, and the accumulation of caseum, indicative of a
hypoxic environment. Infectious bacilli are then released into the airways when the granuloma
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Lymphocyte
Lipid Droplets
Foamy Macrophage
Macrophage
Fibrous Cuff

Figure 1: Schematic of granuloma structure, characteristic of Mtb infection. Genes studied
in this current work are proposed acyl-CoA ligases which will affect the ability to degrade
cholesterol. Lipid droplets within a foamy macrophage are filled with cholesterol that Mtb can
utilize as a carbon source during granuloma progression towards disease.
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cavitates and collapses into the lungs [29, 31-34].
The combined mechanism by which Mtb can thrive in such hostile surroundings and the
process by which it transitions its metabolism are still not fully understood [35-37]. However, it
has been reported that the conversion to a lipid-based metabolism is essential for virulence as well
as for survival of the bacteria in vivo [38]. Host cholesterol, naturally occurring at very high levels
in human diets, is hypothesized to be involved in development of infection by enhancing bacterial
burden in the lung while also impairing immunity to Mtb [26]. As mentioned above, cholesterol is
required for the successful phagocytosis of mycobacteria into macrophages [39]. To ensure
sufficient supply of cholesterol, Mtb may rely on lipid import by host macrophages, to which it
has been reported that mycolic acid strongly interferes with lipid homeostasis of alveolar
macrophages. This process ultimately triggers intracellular accumulation of cholesterol, resulting
in larger cell size and multiple vacuole formation, all of which are typical characteristics of
“macrophage foam cells” [40]. The catabolism of odd-chain-length fatty acids and cholesterol,
especially when used as the main carbon source, yields sufficient acetyl-CoA as well as a sufficient
and toxic amount of propionyl-CoA. A common pathway of propionyl-CoA metabolism in
microorganisms is the methylcitrate cycle, which includes the dedicated enzymes methylcitrate
synthase (MCS), methylcitrate dehydratase (MCD) and methylisocitrate lyase (MCL). The methyl
citrate cycle is essential for propionate metabolism in Mtb. The methylmalonyl pathway, which
yields succinate and provides methylmalonyl CoA from propionyl CoA, is needed for biosynthesis
of methyl-branched fatty acids that are then incorporated into complex bacterial lipids such as the
main virulence lipid phthiocerol dimycocerosate (PDIM). Accumulated succinate, originating
from acetyl-CoA utilization in the glyoxylate cycle, is then used for energy as well as CO2
production [3, 41, 42].
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KstR is a TetR-like transcriptional repressor that is believed to regulate the expression of
83 cholesterol catabolic genes, which are proposed to be involved in metabolism of the A and B
rings as well as coding for b-oxidation enzymes responsible for side chain degradation- including
the enzyme studied here, FadD19A1 [56-59]. Recently it has been demonstrated that FadD17A1
in certain strains lacks a putative binding site for both KstR and KstR2, yielding an unclear picture
of whether it is controlled by the TetR-like repressor [60]. It was recently shown that Mtb
persistence is linked to its ability to import and catabolize cholesterol from its host and confirmed
by deletion of mce4F, an uptake gene in the cholesterol catabolic regulon encoding proteins with
homology to the ABC transporters allowing Mtb to derive both carbon and energy, resulting in a
growth defect when the bacteria were grown on cholesterol [61, 62]. Confirming the importance
of genes in this regulon, it was also demonstrated that cytochrome P450, CYP125, is essential for
growth in the presence of cholesterol alone, or in combination with glycerol [26, 28]. The
accumulated substrate (cholest-4-en-3-one) in a Dcyp125 background had a bacteriostatic effect
on the growth of wild-type Mtb [26, 28]. The intracellular growth region operon (igr) (Rv3545cRv3540c), located in the 83-gene cholesterol degradation locus, is required for in vitro growth
both in macrophages and mice when cholesterol is used as a sole carbon source, but interestingly
is not required for growth on fatty acids [26, 63]. It was observed that the inactivation of the igr
operon lead to defects in bacterial growth on cholesterol alone and in combination with glycerol,
suggesting cell intoxication by cholesterol or its metabolites when the cholesterol degradation
pathway is interrupted [63]. Furthermore, it was noted that blockage of import of cholesterol in
Δmce4F cells attenuated infection in both activated macrophages and mouse models of infection
[37, 63]. Given the importance of the recent findings associated with metabolic growth when
cholesterol is used as a primary source of carbon, and our understanding of the necessary shift to
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lipid metabolism in the glucose-deficient environment of the macrophages where Mtb infects, it is
of the essence to elucidate the cholesterol side chain degradation pathway. It has been
demonstrated that cholest-4-en-3-one inhibits lipid domain formation, thus altering the plasma
membrane’s properties [64, 65]. Due to the observation of decreased permeability for the primary
antitubercular drug rifampin when Mtb accumulated cholesterol in its cell wall, it is speculated
that altering the normal cholesterol degradation pathway to accumulate cholest-4-en-3-one might
render bacterial cell wall more permeable to drugs and xenobiotics [26, 53, 66].
As reviewed by Ouellet et al., several recent studies have identified host cholesterol as the
source of carbon and energy during this stage of infection [26, 43]. The initial steps in cholesterol
catabolism

are

oxidation

at

C3

by

cholesterol

oxidases

or

3-β-hydroxysteroid

dehydrogenase/isomerases (3-β-HSD) and oxidation at C26 by P450 cytochromes (CYP125 and
CYP142), either sequentially and/or simultaneously [44]. Cholest-4-en-3-one (after cholesterol C3
oxidation), 3-β-hydroxy-5-cholestenoic acid (3OHChA) (after cholesterol C26 oxidation), and 3oxo-4-cholestenoic acid (3OChA) (after C3 and C26 oxidations) are the resulting molecules from
initial steps in cholesterol catabolism (Figure 2) [45-48]. It has been hypothesized that FadD19
acts on the 4-cholestenoic acid (C27) intermediate and FadD17 acts on the 4-cholenic acid (C24)
intermediate [1, 49]. Confirmation of this, and elucidation of the remaining steps in the side chain
degradation (C26, C24 and C22-oic substrates) have yet to be fully described. This situation must
be remedied, in the hope of shedding some light on the importance of cholesterol associated with
the virulence of this pathogenic bacterium in vivo, and for potential gene therapeutics [50-55]. We
will review this pathway and some additional steps that we have characterized through this study
to provide more clarification on the degradation pathway.

8

Figure 2. Initial proposed cholesterol side-chain degradation pathway with hypothetic
catabolic intermediates. Released byproducts are labeled in (purple). FadD17A1 and
FadD19A1 are labeled in (red). Their CoA ester derivatives for the acyl-CoA
dehydrogenases FadE26-29 and FadE34 are also labeled but are not investigated here.
Enzymes in (
) show activity in vitro with the substrates, but are not the key players at
this step. Beginning, ending and important intermediate substrates involved are labeled in
(green).
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1.5 Mtb FadD acyl-CoA ligases and their role in cholesterol/fatty acids degradation
The role(s) of FadD enzymes are not fully understood; however, it is known that in the
highly conserved cholesterol catabolic pathway in mycolic acid-containing actinomycetes, these
enzymes are predicted to encode AMP-forming acyl-CoA ligases (Table 1). Initially, these groups
of enzymes were generally classified as synthetases and were thought to have a universal
mechanism involving the formation of acyl-coenzyme A thioesters [67]. Despite their homology
to the acyl-CoA synthetases, recently the FadD enzymes concerned in the present work have been
further classified into two distinct groups. FadD19A1 and FadD17A1 belong to the fatty acid CoA
ligase (FACL) group that use ATP and CoA to thioesterify substrates containing a free carboxylate
(Figure 3A) [68]. Fatty acyl-AMP ligases (FAAL) (e.g. FadD32 enzyme) activate long-chain fatty
acids as acyl-adenylates, which are then transferred to the multifunctional polyketide synthases
(PKS) for further chain extension, allowing for production of various complex lipids essential for
Mtb infection (Figure 3B and Table 1) [68]. These enzymes belong to an acyl-adenylate/thioesterforming group, which may also share two well-conserved motifs (motif I, 161T-S-G-T-T-G-L-PK-G170, and motif II, 302Y-G-T-T-E306) found in the metabolically diverse Pseudomonas genus.
These enzymes, in addition to substrate binding and/or catalysis, are the primary route for fatty
acid activation in Mtb [69, 70]. FACL enzymes such as FadD17A1 and FadD19A1 require
coenzyme A (CoASH) as well as ATP to thioesterify substrates containing a free carboxylate
through a two-step mechanism (Figure 3B) [71]. The esterification of fatty acids to CoA to form
acyl-CoA is a necessary step for utilization of fatty acids by most lipid metabolic enzymes [67,
68]. In Mtb the cholesterol catabolic cluster contains four FadD genes: fadD17A1, fadD18 (a
truncated paralogue of FadD19A1), fadD19A1 and fadD3; identified as Rv3506, Rv3513c,
Rv3515c and Rv3561, respectively, in Mtb strain H37Rv (Figure 4) [72]. Except for fadD18, the
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Table 1: Identification of fatty acid CoA ligases (FACL) and fatty acid AMP ligases (FAAL)
between Mtb and M. smeg: The table details the identified protein product, classification, gene
locus for Mtb as well as the locus for the M. smegmatis orthologue.

Protein
FadD1
FadD2
FadD3
FadD4
FadD5
FadD6
FadD7
FadD8
FadD9
FadD10
FadD11
FadD11.1
FadD12
FadD13
FadD14
FadD15
FadD16
FadD17
FadD18
FadD19
FadD21
FadD23
FadD24
FadD25
FadD26
FadD28
FadD29
FadD30
FadD31
FadD32
FadD34
FadD35

Classification
Possible FACL
Probable FACL
Probable FACL
Probable FACL
Probable FACL
Probable FACL
Probable FACL
Probable FACL
Probable FACL
Possible FACL
Probable FACL
Possible FACL
Possible FACL
Probable FACL
Probable FACL
FACL
Possible FACL
FACL
Probable FACL
(fragment)
FACL
Probable FAAL
Probable FAAL
Probable FAAL
Probable FAAL
FAAL
FAAL
FAAL
FAAL
Probable FACL
FAAL
Probable FACL
Probable FACL
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Mtb locus
Rv1750c
Rv0270
Rv3561
Rv0214
Rv0166
Rv1206
Rv0119
Rv0551c
Rv2590
Rv0099
Rv1550
Rv1549
Rv1427c
Rv3089
Rv1058
Rv2187
Rv0852
Rv3506

M. smeg locus
MSMEG_4952
MSMEG_0599
NA
MSMEG_0257
MSMEG_0131
MSMEG_5086
MSMEG_5295
MSMEG_1098
MSMEG_2956
NA
MSMEG_3131
NA
MSMEG_0304
NA
MSMEG_5291
MSMEG_4254
MSMEG_3566
MSMEG_5908

Rv3513c

NA

Rv3515c
Rv1185c
Rv3826
Rv1529
Rv1521
Rv2930
Rv2941
Rv2950c
Rv0404
Rv1925
Rv3801c
Rv0035
Rv2505c

MSMEG_5914
MSMEG_4731
MSMEG_4731
MSMEG_4731
MSMEG_4731
NA
MSMEG_4731
NA
NA
MSMEG_3465
MSMEG_6393
NA
MSMEG_5649

Figure 3. Differences in mechanism of fatty acid processing, mediated by fatty acid CoA
ligases and fatty acid AMP ligases. (A) Reaction catalyzed by fatty acyl-CoA ligases (FACL).
(B) Reaction catalyzed by fatty acyl-AMP ligases (FAAL). Rectangular box with letter coding
represents the polyketide synthase (PKS) proteins. Fatty acids are activated as acyl-adenylates
and transferred on to the N-terminal PCP domain of PKS proteins. The acyl group is then
loaded at the active site cysteine of the ketosynthase (KS) domain. The acyl transferase (AT)
domain transfers malonyl-CoA (extender unit) on to the ACP P-pant arm, extending the acyl
group by two carbons through a decarboxylative condensation reaction producing CO2.
Ketoreductase (KR) domain reduces ACP-bound intermediates produced. Abbreviations: ATP,
adenosine triphosphate; PPi, pyrophosphates produced through hydrolysis; AMP, adenosine
monophosphate; SH, thiol group; CoASH, Coenzyme A; CO2, carbon dioxide. Figure adapted
from [67, 68]
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RV3505

RV3506

RV3507

FadE27

FadD17A1

PE-PGRS

RV3511

RV3512

RV3513c

RV3514

RV3515c

Family
proteins

FadD18

PGRS
proteins

FadD19A1

PE-PGRS

RV3508
Family
proteins

RV3509c

RV3510c

Proposed
synthetase

Hyp. Cons.
protein
RV3516
echA19

Figure 4. Genomic organization of fadD17A1 (top) and fadD19A1 (bottom) and
surrounding genes of Mtb H37Rv. Diagram illustrates location of both acyl-CoA ligases
concerned with this project, including genes upstream and downstream. Proposed enzymes
for each operon are located beneath the arrows. Enzymes investigated in this work
(FadD17A1 and FadD19A1) are colored in red.
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three other genes encode full-length proteins sharing less than 30% amino acid sequence identity,
suggesting a unique and individual role for each [73, 74].
The role(s) of FadD17A1 and FadD19A1 have been proposed as catalysis of coenzyme A
thioesterification of long-chain fatty acids, but which length of fatty acids they can act upon and
whether there is only one substrate capable of binding with each enzyme to activate esterification
is still unknown. Additionally, it has been reported that the degradation of fatty acids contributes
to the survival and virulence of Mtb and can help alleviate toxicity associated with excess
propionate-CoA [75]. Fatty acid AMP ligases have been reported to be essential during the growth
phase of Mtb, but fatty acids can also be acted upon by fatty acid CoA ligases, and this mechanism
and its contribution to virulence or growth are not fully understood. It is hypothesized that fatty
acid CoA synthetases in Mtb provide new routes for fatty acid activation. When fatty acids are
activated as acyl-adenylates, these proteins redirect the metabolic flux toward biosynthesis of
complex lipidic metabolites. Interestingly, fatty acid AMP ligases have CoASH binding pockets,
but are unable to synthesize acyl-CoA suggesting a mutually beneficial interaction between FACL
and FAAL [42, 62, 68, 76, 77].
1.6 Analysis of M. smegmatis as a model for Mtb and comparison of acyl-CoA ligases between
the two organisms
This project relies heavily on the ability to use M. smegmatis as a model to study Mtb.
Given the numerous differences between the two organisms such as genome size, pathogenicity,
and growth rate (Table 2), M. smegmatis has been heavily exploited in both the past and present
contributing to the understanding of Mtb much faster and more safely than could be done by
working solely with Mtb. M. smegmatis is a soil-dwelling saprophytic species, and distant relative
of M.tuberculosis (Table 2) [78, 79]. This avirulent species is fast growing, yielding colonies much
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Table 2: Table of Mycobacterium models used for Mtb research. Listed below are the
current models used to expedite knowledge of Mtb pathways and virulence factors essential
for progression of the disease. The table details differences in genome size and growth rate,
as well as the advantages associated with carrying out TB research in each model. Table was
adapted from [78].

Species
M. smegmatis

Genome
Size (MB)
7
•
•

M. marinum

6.6

•
•

M. bovis (BCG)

4.3

•
•

M. tuberculosis

4.4

Growth Rate
4 h liquid
2-3 days colonies

10 h liquid
1-week colonies

22 h liquid
2-3 weeks
colonies
• 22 h liquid
• 2-3 weeks
colonies
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Advantages
1. Rapid growth of culture
2. Ease of manipulation for
mutant strain generation
3. Elevated level of conservation
among FadD enzymes
4. Able to grow at elevated levels
of cholesterol for metabolite
profiling
1. Faster growth than Mtb
2. TB-like diseases in ectotherms,
and passage from ectotherms
to humans
3. Ability to study secretion
systems essential for Mtb like
ESAT-6
1. Conserved genes are 99%
identical to those in Mtb
2. Attenuated
1. Causative agent of TB
2. Results directly applicable
3. Contains all virulence factors
needed to identify new targets
which may lack in all other
models.

more quickly than Mtb. M. smegmatis is a convenient model, especially in terms of its ease of
genetic manipulation, which will be utilized heavily in this paper to elucidate functions of genes
through mutation studies involving metabolic profiling. When comparing FadD enzymes between
M. smegmatis and Mtb, there is a high degree of conservation among the homologs for both
FadD17A1 and FadD19A1, allowing M. smegmatis to be an applicable model to study the effect
and function of these enzymes. It cannot be ignored, however, that greater conservation for both
enzymes exists in M. bovis, as well as M. marinum; indicating that slower growing mycobacterial
species are more closely related (Figures 5-6). Due to M. smegmatis’s increased genome size
(Table 2) it must also be mentioned that multiple copies of FadD enzymes occurs more frequently
in M. smegmatis than in other mycobacterium models. Because of this, it is important to note that
a new naming system for the FadDs discussed in this paper has been developed to avoid confusion.
Concerning FadD19A1 in Mtb; M. smegmatis has two copies of this protein, both sharing
conservation. The primary homologue in M. smegmatis termed “FadD19A2,” is more closely
related (86% sequence identity) to FadD19A1 in Mtb than is the second copy of FadD19 in M.
smegmatis, termed “FadD19B1” (35% sequence identity) (Figures 6 and 7). Interestingly, most of
the acyl-activating enzyme consensus motif, putative AMP binding site, and putative active site
are conserved among all three versions even with the relatively low sequence identity for
FadD19B1, indicating some redundancy in M. smegmatis concerning this enzyme (Figure 7).
Because of this naming system, and for consistency, we have also decided to name the M.
smegmatis homologue of FadD17A1 “FadD17A2” even though there is only one copy of this
protein in both organisms. FadD17A2 shares 66% sequence identity as FadD17A1 in Mtb (Figure
5). This naming system will be more utilized in Chapter 3 of this project, which deals with
metabolic profiling of mutant strains in M. smegmatis.
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Figure 5: FadD17A1 and FadD17A2 conservation analysis. Demonstrates the analysis of
homology between FadD17A1 from Mtb and FadD17 homologues from mycobacterial models
including FadD17A2 from M. smegmatis. Analysis was conducted using the maximum
likelihood method with protein sequences obtained from NIH-BLAST, and displays both the
tree analysis (top) and estimates of evolutionary divergence among FadD17 homologs (bottom).
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Figure 6: FadD19A1, FadD19A2 and FadD19B1 conservation analysis. Demonstrates the
analysis of homology between FadD19A1 from Mtb and FadD19 homologues from
mycobacterial models including FadD19A2 and FadD19B1 from M. smegmatis. Analysis was
conducted using the maximum likelihood method with protein sequences obtained from NIHBLAST and displays both the tree analysis (top) and estimates of evolutionary divergence
among FadD19 homologs (bottom).
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Figure 7: Sequence alignment among FadD homologues. Sequence alignment was
conducted using NCBI’s BLAST website, and graphed to show acyl-activating enzyme
consensus motif, putative AMP binding site, and putative active site (red boxes). Many of these
amino acids are shared among the three motif’s. The asterisks at the bottom indicate
conservation among these sites. Color legend: Red, small, + charged hydrophobic including
aromatic-Y; Blue, acidic; Magenta, basic-H; Green, hydroxyl + sulfhydryl + amine + G.
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1.7 Significance
Although TB has been extensively studied in the past, and is well characterized, the
emergence of MDR strains has halted the progress of eradicating this epidemic. Over the past five
years, much attention has been focused on elucidating the breakdown of the A and B rings of
cholesterol, but very little is known about the fate of the C and D rings [3]. It has also been
proposed that the side chain of cholesterol is metabolized by β-oxidation (like fatty acids), but the
specific genes involved in this process are not fully characterized. Therefore, the main goal of this
work is to improve this characterization, in hopes of adding to the body of knowledge of
cholesterol catabolism by Mtb. Currently available literature involving structural and biochemical
data on β-oxidation enzymes in the cholesterol regulon is limited, and examining the effects that
deletion of other genes in this regulon has on the growth of Mtb on cholesterol substrates is
essential to evaluate the enzymatic gene products regarding their essentiality in Mtb metabolism,
and to allow for the creation of new therapeutics targeting these genes. In light of the observation
that more than 5% of newly emerging strains of Mtb are currently untreatable with any drugs, it is
essential that the complete pathway of cholesterol catabolism be fully understood to seek new and
innovative treatments for MDR and XDR strains [25, 80, 81]. Given the large number of genes
encoding β-oxidation enzymes in the cholesterol catabolic regulon, it is essential to combine
genetic and state-of-the-art activity-based metabolomics approaches (such as those described in
Aim 2 of this investigation) to validate them as targets for the potential development of new
therapeutics designed to treat MDR-TB, XDR-TB, “resistance beyond XDR-TB” strains, and even
patients who are immunocompromised. The unique approach we have chosen to carry out this
metabolic profiling of mutant strains, as well as an activity-based metabolomics analysis, will
allow for the unbiased discovery of enzymatic activities encoded by genes with unknown function
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(FadD17A1 and FadD19A1), and will also be useful in applying the research findings to add to
the body of knowledge and further characterize the cholesterol degradation pathway in Mtb.
1.8 Specific aims and hypothesis
This work investigates the catabolic capabilities of two Mtb acyl-CoA ligases (FadD17A1
and FadD19A1) to elucidate their role(s) in the cholesterol side-chain degradation pathway and
identify their physiological substrate(s). Although much is known about certain genes responsible
for the initiation of the cholesterol degradation pathway (such as the initial steps in cholesterol
catabolism, which include the oxidation of C26 (by P450 cytochromes, CYP125 and CYP142),
the full mechanism after these initial steps is not entirely characterized. This work intends to
elucidate the existence of pathways involving genes located within the cholesterol catabolic
regulon, including our proposed fadD genes, which could be capitalized on to develop new
therapies for MDR-TB strains which are untreatable using current methods. We will focus on the
following aims:

Aim 1: Elucidating enzymatic activities in vitro using recombinant Mtb acyl-CoA
ligases FadD17A1 and FadD19A1. Genes coding for FadD17A1 and FadD19A1 were amplified
by PCR and sub-cloned into plasmid vectors for expression of recombinant proteins in Escherichia
coli and Mycobacterium smegmatis to carry out in vitro enzymatic assays to identify potential
substrates not already known. As an enzymatic activity assay, interaction through product
formation was measured in the presence of ATP, coenzyme A (CoA), and commercially available
or synthetic steroid and fatty acid substrates. Product formation was detected and quantified using
a highly sensitive luciferase reporter assay.
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Aim 2: Growth, metabolic profiling and activity-based metabolomics profiling of M.
smegmatis DfadD17A2, DfadD19A2, and DfadD19B1 mutant strains in combination with
DkstD utilizing various media. A novel screening method was used to identify accumulated
metabolites extracted in single, double and triple deletion mutants of fadD17A2, fadD19A2,
fadD19B1 and kstD of M. smegmatis grown in the presence of cholest-4-en-3-one. Accumulated
metabolites will be profiled by high-resolution mass spectrometry after addition of recombinant
Mtb FadD17A1 and/or FadD19A1 enzymes.

Aim 3: Growth and metabolic profiling of M. smegmatis DfadD17A2, DfadD19A2 and
DfadD19B1 mutant strains utilizing various media. Single, double and triple deletion mutants
of fadD17A2, fadD19A2 and fadD19B1 were cultured in the presence of cholest-4-en-3-one alone
as well as more complex media with multiple carbon sources, including cholest-4-en-3-one and
glucose. Extracted accumulated metabolites will be investigated by a high-resolution mass
spectrometry profiling assay to further characterize the cholesterol degradation pathway for these
acyl-CoA ligases.

Hypothesis: We hypothesize that the utilization of host cholesterol reshapes Mtb’s
metabolism as an adaptive mechanism for survival in macrophages and that these two acyl-CoA
ligases (FadD17A1 and FadD19A1) play an essential role in the cholesterol degradation process.

22

Chapter 2: Elucidating enzymatic activities in vitro using recombinant Mtb
acyl-CoA ligases FadD17A1 and FadD19A1
2.1: Methods
Preparation of recombinant Mtb acyl-CoA ligases FadD17A1 and FadD19A1 in E. coli
utilizing His-tag system:
Genes coding for FadD17A1 and FadD19A1 were amplified by PCR using the primers
listed in Table 3 and sub-cloned into pET-derived vectors for expression of recombinant proteins
with an N-terminal histidine tag produced in E. coli by co-expression with the chaperones
GroEL/ES and IPTG induction. 1 ng of plasmid DNA was introduced into E. coli BL21DE3
containing pGro7, incubated on ice for 20 minutes (min) followed by a 90 second (s) heat shock
at 42°C, and recovered for 60 min in SOC medium at 37°C, 250 rpm. Cells were plated on LB
plates containing 50µg/mL of kanamycin (K50) and 34 µg/mL chloramphenicol (Cm34). Single
colonies were picked and used to inoculate a 50 mL starter culture in LB media containing (K50
and Cm34) that was grown overnight at 37°C, with shaking at 250 rpm. Using a 1:1000 dilution, 4
L of LB media were inoculated containing (K50 and Cm34) and 0.1% final concentration (w/v) of
arabinose for chaperone induction. When culture reached an OD600 of 0.5, IPTG was added to a
final concentration of 0.5 mM and growth continued for 24 hours (h) at 37°C, 200 rpm. Cells were
harvested at 4000 ´g for 30 min and kept frozen at -80°C until further use.

Preparation of recombinant Mtb acyl-CoA ligases FadD17A1 and FadD19A1 in M.
smegmatis utilizing His-tag system:
Genes coding for FadD17A1 (Figure 8) and FadD19A1 were amplified by PCR (Table 3),
and sub-cloned into an engineered M. smegmatis vector (pYUB28bLIC), which also carries the
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Table 3: Plasmid and primer design for expression of His/Strep-tagged FadD17A1,
FadD19A1 FadD19B1 in E. coli and/or M. smegmatis: The below table illustrates the
strain used to express proteins, the vector used, and the design of primers used to amplify
inserts by PCR.

Protein + tag

Strain

MtbFadD19A1HIS (N-term)

BL21DE3
+pGro7

MtbFadD19A1STREP (Nterm)

mc24517

MtbFadD19A1HIS (N-term)

mc24517

M.smegFadD19B1STREP (Nterm)

mc24517

MtbFadD17A1HIS (C-term)

mc24517

Primer design
FWD: 5’-TACTTCCAATCCAATGTGGC
CCTGAATATTGCC-3’
REV: 5’-TTATCCACTTCCAATCGACCC
ATGTCGACCTTC-3’
FWD: 5’-GAAAAATCCGGAAATGTGG
CCCTGAATATTGCC-3’
REV: 5’-GGCCGCAAGCTTAATCGACC
CATGTCGACCTTC-3’
FWD: 5’-TACTTCCAATCCAATGTGGC
CCTGAATATTGCC-3’
REV: 5’-TTATCCACTTCCAATCGACCC
ATGTCGACCTTC-3’
FWD: 5’-GAAAAATCCGGAAATCCCG
AGTGGACGATAGGC-3’
REV: 5’-GGCCGCAAGCTTAATGATC
GGGTCGTACATCGACT-3’
FWD:5’-TACCATGGCTCCCACTCACCC
GACC-3’
FWD:5’-CGAAGCTTAATCGGCCACAC
CGGAT-3’
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Vector
pLIC-HK

pYUB28bLIC

pYUB28bLIC

pYUB28bLIC

pYUB28bLIC

Figure 8: pYUB28bLIC circular plasmid design (top) for expression of His-tagged
FadD17A1 in M. smegmatis and linear map illustrating tag, operators, and ribosomal
binding site (bottom): Insertion region (in red) is marked by Fwd and Rev primers (in purple)
in plasmid and was constructed to yield C-terminal 6X-His tagged FadD17A1 in
Mycobacterium smegmatis.
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T7 RNA polymerase gene. Protein expression was performed in an auto-induction media, which
allows the expression of the T7 RNA polymerase when cells start to utilize lactose after depletion
of glucose [82]. Recombinant protein obtained for FadD17A1 has a C-terminal histidine tag and
an N-terminal histidine tag for FadD19A1. 1 ng of plasmid DNA was electroporated into M.
smegmatis mc24517 cells using a 0.2-cm cuvette with resistance=1000Ω, Q=25µF, V=2.5kV. Cells
were recovered and added to 500 µL of 7H9 media containing Middlebrook OADC (SigmaAldrich) and 05% Tween-80 and allowed to incubate for 3 h at 37°C, 200 rpm. Cells were then
plated on 7H10 plates with OADC containing 50 µg/mL of hygromycin. Single colonies were
picked and used to inoculate a 25 mL starter culture in 7H9 media containing 50 µg/mL of
hygromycin that was grown overnight at 37°C, with shaking at 200 rpm. Using a 1:1000 dilution
to ensure synchronization, 4 L of ZYM-5052 auto-induction media containing 50 µg/mL of
hygromycin were inoculated and grown for 48 h at 37°C, 180 rpm. Cells were harvested at 4000
´g for 30 min and frozen at -80°C until needed.

Preparation of M. smegmatis acyl-CoA ligases FadD19B1 and recombinant Mtb FadD19A1
in M. smegmatis utilizing Strep-tag system:
Genes coding for FadD19B1 and FadD19A1 were amplified by PCR (Table 3) and subcloned into modified pET-derived vector (pYUB28bLIC) for expression of recombinant proteins
with an N-terminal Strep tag produced in M. smegmatis (Figures 9-10). Protein expression was
performed in the more sensitive Strep-tag system from GE, utilizing an N-terminal twin Strep-tag
to achieve higher purity. 100 ng of plasmid DNA was electroporated into M. smegmatis MC24517
cells using a 0.2-cm cuvette with resistance=1000 Ω, Q=25 µF, V=2.5 kV. Cells were recovered
and added to 500 µL of 7H9 media containing Middlebrook OADC (Sigma-Aldrich) and .05%
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Figure 9: pYUB-28bLIC-Strep circular plasmid design (top) for expression of Streptagged FadD19A1 (Mtb) in M. smegmatis and linear map illustrating tag, operators, and
ribosomal binding site (bottom): Insertion region is marked by Fwd and Rev primers (in
purple) in plasmid, and was constructed to yield N-terminal twin Strep-tagged FadD19A1 in
Mycobacterium smegmatis.
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Figure 10: pYUB-28bLIC-Strep circular plasmid design (top) for expression of Streptagged FadD19B1 (M. smeg) in M. smegmatis and linear map illustrating tag,
operators, and ribosomal binding site (bottom): Insertion region is marked by Fwd and
Rev primers (in purple) in plasmid, and was constructed to yield N-terminal twin Streptagged FadD19B1 in Mycobacterium smegmatis.
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Tween-80, and allowed to incubate for 3 h at 37°C, 200 rpm. Cells were then plated on 7H10 plates
with OADC containing 50 µg/mL of hygromycin. Single colonies were picked and used to
inoculate a 25 mL starter culture in 7H9 media containing 50 µg/mL of hygromycin that was
grown overnight at 37°C, with shaking at 200 rpm. Using a 1:1000 dilution to ensure
synchronization, 4 L of ZYM-5052 auto-induction media containing 50 µg/mL of hygromycin
were inoculated and grown for 48 h at 37°C, 180 rpm. Cells were harvested at 4000 ´g for 30 min
and frozen at -80°C until needed.

Lysis of cells for extraction of recombinant Mtb acyl-CoA ligases FadD17A1 and FadD19A1
utilizing His-tag system:
Cells were resuspended in 50 mL of ice-cold lysis buffer (50 mM Tris-Cl, 150 mM NaCl,
10% glycerol, 2.5 mM imidazole) and were kept on ice at all times. Lysozyme was added at 0.5
mg/mL and incubated on ice for 30 min along with protease inhibitor cocktail (Pierce Protease
Inhibitor Cocktail Tablet). Sonication was carried out on ice and with frequent pauses to prevent
overheating of sample, as protein is temperature sensitive. Before, during and after sonication 100
µL of 100mM phenylmethylsulfonyl fluoride (PMSF), solubilized in isopropanol, was added to
lysate to prevent proteolysis. Lysate was then centrifuged at 10,000 rpm for 45 min to remove
insoluble fraction. Supernatant was carefully removed and centrifuged again at 100,000 ´g for 1 h
to pellet membrane-bound fraction. Finally, supernatant was filtered through a 0.45 µm filter
(Millex) to remove particulates before application onto affinity columns.

Lysis of cells for extraction of recombinant Mtb acyl-CoA ligases FadD19A1 and FadD19B1
utilizing Strep-tag system:
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Cells were resuspended in 50 mL of ice-cold lysis buffer (100 mM Tris-Cl, 500 mM NaCl,
10% glycerol, 1 mM EDTA, 50 mM DTT, 0.2% Triton X-100) and were kept on ice. Lysozyme
was added at 0.5 mg/mL and incubated on ice for 30 min along with protease inhibitor cocktail
(Pierce Protease Inhibitor Cocktail Tablet). Sonication was carried out on ice and with frequent
pauses to prevent overheating of sample. Before, during and after sonication 100 µL of 100 mM
phenylmethylsulfonyl fluoride (PMSF), solubilized in isopropanol, was added to lysate to prevent
proteolysis. Lysate was then centrifuged at 10,000 rpm for 45 min to remove insoluble fraction.
Supernatant was carefully removed and centrifuged again at 18,000 rpm for 1 h to pellet
membrane-bound fraction. Finally, supernatant was filtered through a 0.45 µm filter (Millex) to
remove particulates before application onto affinity columns.

Purification of Mtb FadD17A1 and FadD19A1 ligases utilizing immobilized metal ion affinity
chromatography (Ni2+):
HP-HisTrap columns (5 mL) were purchased from GE Healthcare, and equilibrated using
5 column volumes of lysis buffer (buffer A). Protein was manually loaded onto column using
peristaltic pump (GE Healthcare). After loading, column was again washed with 5 column volumes
of buffer A, and flow-through was collected at each step for analysis on SDS gel. 5 mL fractions
were collected using a manual gradient maker (Bio-Rad Model 2110 Fraction Collector) with 10
column volumes of buffer B (50 mM Tris-Cl, 10% glycerol, 5 mM NaCl, 10 mM imidazole) and
10 column volumes of buffer C (50 mM Tris-Cl, 10% glycerol, 5 mM NaCl, 150 mM imidazole)
with the end fractions reaching 100% C. Buffers B and C were decreased in NaCl concentrations
to prepare protein for additional affinity chromatography without the need for dialysis to remove
excess salt. All fractions were analyzed on 11% SDS gels, and tubes with the cleanest and most
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concentrated amount of either FadD17A1 or FadD19A1 were pooled, concentrated (Millipore
50,000 MWCO membrane), and prepared for the next affinity chromatography application.

Purification of Mtb FadD17A1 and FadD19A1 ligases utilizing anion exchange affinity
chromatography:
Pooled and concentrated portions from previous Ni2+ purification was loaded onto HiTrap
Q FF-5 mL column (GE Healthcare) using a peristaltic pump. Once loaded, column was washed
with buffer A (50 mM Tris-Cl, 5 mM NaCl, 10% glycerol) and flow-through collected for SDS
analysis. 5 mL fractions were collected using a manual gradient maker with 10 column volumes
of buffer A and 10 column volumes of buffer B (50 mM Tris-Cl, 10% glycerol, 500 mM NaCl)
with the end fractions reaching 100% B. All fractions were analyzed on 11% SDS gels, and
cleanest fractions were pooled, concentrated (Millipore 50,000 MWCO membrane) and dialyzed
overnight at 4°C in 50 mM Tris-Cl containing 10% glycerol and 150 mM NaCl.

Purification of Mtb FadD19A1 and M. smegmatis FadD19B1 ligases utilizing Streptactin
sepharose.
HP-StrepTrap-5 mL column (GE Healthcare), were equilibrated using 5 column volumes
of lysis buffer (Buffer A). Protein was manually loaded onto column using peristaltic pump (GE
Healthcare). After loading, column was washed with 5 column volumes of buffer A, and flowthrough was collected at each step for analysis on SDS gels. 5 mL fractions were collected using
a manual gradient maker (Bio-Rad Model 2110 Fraction Collector) with 10 column volumes of
buffer A (100 mM Tris-Cl, 500 mM NaCl, 10% glycerol, 1 mM EDTA, 50 mM DTT, 0.2% Triton
X-100) and 10 column volumes of buffer B (100 mM Tris-Cl, 500 mM NaCl, 10% glycerol, 1 mM
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EDTA, 50 mM DTT, 0.2% Triton X-100, 2.5 mM desthiobiotin) with the end fractions reaching
100% B. All fractions were analyzed on 11% SDS gels, and tubes with the cleanest FadD19A1 or
FadD19B1 were pooled, concentrated (Millipore 50,000 MWCO) and dialyzed overnight at 4°C
in 50 mM Tris-Cl, 10% glycerol, 150 mM NaCl.

Enzymatic activity of purified recombinant Mtb acyl-CoA ligases FadD17A1, FadD19A1
and M. smegmatis FadD19B1:
Substrate preference was tested using AMP-GLOÔ assay (Promega) for both FadD17A1
and FadD19A1 from Mtb and FadD19B1 from M. smegmatis (Figure 11). The activity of purified
ligases was assessed using a range of saturated fatty acids (C5-C18) (Sigma Aldrich) as well as
unsaturated and polyunsaturated C18 fatty acids (oleic, linoleic) (Sigma Aldrich). Steroid acids
(23,24-bisnor-5α-cholenic acid-3-one, 5-cholenic acid-3β-ol, 4-cholenic acid-3β-ol, 25-R and 25S isomers of 3-oxo-4-cholestenoic acid as well as 25-R and 25-S isomers of 3b-hydroxy-5cholestenoic acid (C26-oic)) (Avanti, Steraloids) were also tested. Reaction mixtures were
completed in triplicates each time tested and were conducted in 96-well white plates (Thermo
Fisher) to minimize signal carry over from neighboring wells. A control completed in triplicates
was run with each plate (all components including enzyme without substrate) to ensure no turnover
of ATP was being carried out by contaminating proteins, or chaperone present in reactions.
Reactions (25 µl) contained all necessary co-factors including MgCl2, pure CoA and ATP
(Promega) and buffers to perform acyl-CoA ligase activity testing with our purified enzymes
(Table 4). Once all components of reaction were combined, reactions were initiated by addition of
enzyme, and incubated at 25°C at varying times (substrate dependent) to ensure only 10%
conversion and quantified using highly pure AMP standards supplied with AMP-GLOÔ kit
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Protein
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Figure 11: Illustration describing expression and activity testing of purified recombinant
FadD19A1, FadD17A1 and FadD19B1. Details expression of recombinant Mtb FadD19A1,
FadD17A1 and M. smegmatis FadD19B1 (top). Activity testing was conducted using
Promega’s AMP GLOÔ kit which detects released AMP upon binding of the ligases and
attachment of CoA to the substrate, through luciferase activity (bottom).
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Table 4. Composition of reaction mixture for the reconstitution of enzymatic activity of
purified recombinant FadD17A1, FadD19A1, or FadD19B1. Reaction buffers, co-factors,
and substrate, excluding enzyme, were pooled together and aliquoted to avoid pipetting errors.
Reaction was then initiated by addition of enzyme last to ensure that all reactions were
synchronized and incubated at 25°C for varying time points. After quenching, detection of
product formation was analyzed through luciferase reads on a Luminoskan Ascent plate reader.
Smaller quenching volumes are for assays performed in low volume plates.

Chemical compound (reaction)

Final concentration

Water

Complete to 25 µL

Hepes buffer

50 mM

Coenzyme-A-lithium salt

0.5 mM

Pure ATP (Promega AMP-GLOÔ)

2.5 mM

MgCl2

5 mM

Substrate (solubilized in DMSO)

100 µM

Recombinant enzyme (FadD17A1, FadD19A1 or
FadD19B1)
DMSO

50 nM
0.5 %

Chemical Compound

Volume used

(quench and detection)
AMP-GLOÔ reagent I

25 or 10 µL

(Quenching solution)
AMP detection solution

50 or 20µL
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(Promega). After incubation, reactions were quenched with 25 µl of AMP-GLOÔ Reagent I,
centrifuged at 3000 rpm for 1 min to remove bubbles, and shaken briefly every 20 min for 1 h.
After incubation, 50 µl of AMP detection solution (Promega) was added to each well, centrifuged
at 3,000 rpm for 1 min, and shaken again briefly every 20 min for 1 h in the dark. After the final
incubation, the plate was immediately analyzed using a Luminoskan Ascent plate reader
(Labsystems).

Steroid preference of purified recombinant Mtb acyl-CoA ligase FadD19A1:
Steroid substrate preference was tested using AMP-GLOÔ assay (Promega) for
FadD19A1 from Mtb. The activity of purified ligases was assessed using steroid acids (23,24bisnor-5α-cholenic acid-3-one, 5-cholenic acid-3β-ol, 4-cholenic acid-3β-ol, 25-R and 25-S
isomers of 3-oxo-4-cholestenoic acid as well as 25-R and 25-S isomers of 3b-hydroxy-5cholestenoic acid (C26-oic)) (Avanti, Steraloids). Reaction mixtures were completed in triplicates
each time tested and were conducted in low volume 96-well white plates (Thermo Fisher) to
minimize signal carry over from neighboring wells. A control completed in triplicates was run
with each plate (all components including enzyme without substrate) to ensure no turnover of ATP
was being carried out by contaminating proteins, or chaperone present in reactions. Reactions were
carried out as described above at various substrate concentrations and contained all necessary cofactors including MgCl2, pure CoA and ATP (Promega) and buffers to perform acyl-CoA ligase
activity testing with purified enzymes (Table 4). Once all components of reaction were combined,
reactions were initiated by addition of enzyme and incubated at 25°C for 7 min to ensure less than
10% conversion and quantified using highly pure AMP standards supplied with AMP-GLOÔ kit
(Promega). After incubation, 10 µl of the reactions were transferred to a new plate and immediately
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quenched with 10 µl of AMP-GLOÔ Reagent I, centrifuged at 3000 rpm for 1 min to remove
bubbles, and shaken briefly every 20 min for 1 h. After incubation, 20 µl of AMP detection solution
(Promega) was added to each well, centrifuged at 3000 rpm for 1 min, and shaken again briefly
every 20 min for 1 h in the dark. After the final incubation, the plate was immediately analyzed
using a Luminoskan Ascent plate reader (Labsystems).

2.2: Results
Purification of the FadD acyl-CoA ligases was a difficult journey that took a lot longer than
expected. When purifying FadD17A1, the protein came out clean with very little contaminating
proteins utilizing the pYUB-28b 6XHis-tag (C-term) vector for expression in M. smegmatis
(Figure 12). To purify this protein, three affinity chromatography purifications were utilized, as
mentioned above. First, immobilized metal ion affinity was used, followed by anion exchange
affinity, and then samples were reloaded onto a nickel column for a second round of immobilized
metal ion affinity chromatography. Purification of FadD19A1 was much more difficult to purify
and resulted in a recombinant protein that appeared much “dirtier” on an SDS gel at the end of
purification following the same steps from above. Initial purification was done utilizing E. coli
(data not shown) and was then attempted in M. smegmatis using the same purification techniques
and tag method resulting in a protein that appeared very similar to what was obtained utilizing E.
coli (Figure 12). It was at this time we decided to carry all our protein expressions out in a more
“natural” host such as M. smegmatis, as opposed to E. coli, to be able to potentially identify posttranslational modifications on the proteins that may be significant to its activity for future analysis.
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Figure 12: SDS-PAGE analysis of purified Mtb FadD17A1, FadD19A1, and M. smegmatis
FadD19B1: Recombinant proteins were expressed in M. smegmatis and ran on an 11% SDSPAGE gel after purification by either His-Tag or StrepTactin affinity chromatography.
Purification attempts with buffers utilizing detergent, increased salt concentration and use of
reducing agents are labeled (#2).
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Many attempts were made to obtain “cleaner” protein, including modifications to the binding and
elution buffers, but were unsuccessful (Figure 12). At this time, we decided to carry over
expression into the same vector but utilize a more sensitive twin Strep-tag purification method
(Figure 9) to clean up the purification of FadD19A1. We attempted this, utilizing the recommended
buffer systems that came with the column and noticed that again we were getting contaminating
proteins that were almost identical to all the previous preparations. We then, as a last resort,
increased NaCl in buffers to 1.0 M, added a reducing agent (DTT) as well as a surfactant (TritonX100) which seemed to give us the cleanest batch of protein that was able to be obtained for
FadD19A1 (Figure 12-labeled FadD19A1#2). When we realized that M. smegmatis had two copies
of FadD19, according to literature and naming on NCBI, we decided to also purify M. smegmatis
FadD19B1 using the same buffers as above, (Figure 12) to test whether its activity would resemble
that of FadD19A1 considering its lower level of sequence identity to FadD19A1 (Figures 6 & 7).
Interestingly, this protein appears to have been purified, utilizing the same method as mentioned
above, with fewer contaminating bands than the FadD19A1 protein.
Once purified recombinant protein was obtained for FadD17A1, FadD19A1, and
FadD19B1, activity testing was carried out using the above-mentioned protocol with Promega’s
AMP-GLOÔ kit. This kit generates light signal through luciferin/luciferase from any reaction that
produces AMP as a reaction product (Figure 11). The kit is a versatile system that monitors the
concentration of AMP released through our acyl-CoA ligases’ activity during enzymatic testing in
a high throughput format and with stable luminescence signal that is quantified using standards
provided with the kit.
Activity testing was carried out for both enzymes using steroid substrates available at the
time, encompassing C22-C27 acid intermediates of cholestenone degradation predicted to be acted
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upon by the ligases investigated in this study. For FadD17A1, as predicted, 4-cholenic and 5cholenic acid (C24) substrates were preferred above all other steroids tested, with slight preference
for 4-cholenic over 5-cholenic acid (Figure 13). It must be noted however, that FadD17A1 was
able to turn over all substrates tested, including the unexpected 23,24-bisnor-chol-1,4-dienic acid
(C22), 23,24-bisnor-5α-cholenic acid-3-one (C22), and the 25-R and 25-S isomers of 3-oxo-4cholestenoic acid as well (C27) (Figure 13). These results suggest slight redundancy of function
concerning FadD17A1; however, the degree of turnover for other substrates compared to turnover
for its highly preferred 4-cholenic and 5-cholenic acid (C24) substrates, indicates a strong
preference does exist for FadD17A1.
Activity testing for FadD19A1, as predicted, showed a strong preference for the 25-R and
25-S isomers of 3-oxo-4-cholestenoic acid, with preference for the S isomer over R, as expected,
since this is the physiological substrate produced by the P450 enzymes (Figure 13) [26, 28]. These
results are consistent with literature previously describing the function of FadD19A1 [49]. Again,
redundancy is suggested by the activity with 4-cholenic and 5-cholenic acid (C24) substrates
(Figure 13) but is consistent with the literature previously describing activity associated with C24
sterols [1]. Unexpectedly, FadD19A1 was also able to catalyze attachment of CoA onto 23,24bisnor- chol-1,4-dienic acid (C22) and 23,24-bisnor-5α-cholenic acid-3-one (C22) substrates, but
to a much lesser extent than its preferred C27 sterol substrate (Figure 13). These results again
reinforce that some redundancy exists when studying the activity of these enzymes in vitro, but
still show a high degree of specificity towards the expected substrates.
The next goal was to demonstrate any activity differences existing between FadD19A1 and
FadD19B1 (the second copy of FadD19A1) in M. smegmatis. When looking at the activity of
FadD19B1, we can see almost an identical trend to that of its relative FadD19A1 (Figure 13). Key
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Figure 13. Substrate preference of steroids for FadD17A1 (top), FadD19A1 (middle) and
FadD19B1 (bottom): Reactions were run with 50 nM of purified recombinant Mtb FadD19A1
or FadD17A1 and 100 µM of substrate. Reactions were run using the Promega AMP-Glo™
Assay and were quenched at 10% conversion, ensuring product formation was less than 10 µM,
established by a linear calibration curve of AMP. Experiment was conducted in triplicates with
three separately purified preparations of proteins. Representative figure of three biological
replicates performed in triplicates.
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differences include the slight preference for 5-cholenic over 4-cholenic acid (C24), and the
differences in overall activity (Figure 13). Activity assays were conducted with the same
concentration of both protein and substrates, but activity was around 2-fold less for both 4-cholenic
and 5-cholenic acid (C24), ~52 fold less for the 25-R isomer of 3-oxo-4-cholestenoic acid, and
~14 fold less for the 25-S isomer of 3-oxo-4-cholestenoic acid compared to FadD19A1. When
evaluating specificity for steroid substrates, we can see that both FadD19B1 and FadD19A1 have
a clear preference for the 25-S isomer of 3-oxo-4-cholestenoic acid (Figure 13). These results
confirm that the two proteins are capable of acting on similar substrates, even though they have
only ~35% sequence identity, and confirm that the important motifs are conserved between them
allowing similar substrate specificity. It can be hypothesized that the differences in identity,
however, could contribute to the noticeable difference in activity rate between FadD19A1 and
FadD19B1. From these data we can conclude that FadD19A1 is the key player in regards to activity
on the above-mentioned substrates, which enzyme in M. smegmatis corresponds to homologue
FadD19A2, rather than FadD19B1.
After enzymatic testing with our available substrates, we decided to elucidate more indepth substrate specificity for the 25-R and 25-S isomers of 3-oxo-4-cholestenoic acid as well as
the 25-R and 25-S isomers of 3b-hydroxy-5-cholestenoic acid (C27) for FadD19A1. What we
observed was an unexpected high substrate affinity for the 25-R isomer of 3b-hydroxy-5cholestenoic acid (C27) at 5µM over all other substrates tested (Figure 14). This substrate,
however, demonstrated a high level of product inhibition at concentrations above 5µM all the way
up to 100µM, as did the 25-S isomer of 3b-hydroxy-5-cholestenoic acid (C27) above 25µM; a
mechanism described previously with acetyl-CoA synthetases and their CoA products [83, 84].
The 25-S isomer of 3-oxo-4-cholestenoic acid seemed to display the least amount of product
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Figure 14. Elucidation of substrate preference of steroids with purified FadD19A1:
Reactions were ran with 50 nM of purified recombinant Mtb FadD19A1 and varying
concentrations of substrate. Reactions were ran using the Promega AMP-Glo™ Assay utilizing
the low volume method and using low volume 96 well plates. Reactions were quenched at 10%
conversion, ensuring product formation was less than 10%, established by a linear calibration
curve of AMP. Representative figure of two biological replicates performed in triplicates.
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inhibition even at concentrations reaching 100µM (Figure 14). Consistent with our previous data,
we were still able to show a strong preference for the 25-S over 25-R isomers of 3-oxo-4cholestenoic acid.
Because of our knowledge that our acyl-CoA ligases are promiscuous in the sense that they
can turn over both fatty acids as well as steroids, we decided to investigate testing with fatty acid
substrates (saturated) from C5-C18, as well as unsaturated and polyunsaturated C18, utilizing
commercially available substrates. For FadD17A1, enzymatic testing revealed that this enzyme
has a low activity on short chain saturated fatty acid substrates, while preferring mid-chain length
saturated fatty acids (C11S) (Figure 15). When testing longer chain fatty acids (C13-C18S),
FadD17A1 displayed similar affinity to that of the short chain fatty acid (C5S). Interestingly, when
tested with unsaturated (C18U) and polyunsaturated (C18-2U) long chain fatty acids, activity was
~12 fold and ~28 fold higher, respectively, in comparison with saturated C18, indicating a strong
preference for unsaturated and polyunsaturated fatty acids (Figure 15). We suspect this drastic
increase in activity may correspond to a more proper docking into the active site of FadD17A1,
due to the kinks arising in the structure of the fatty acids upon unsaturation and polyunsaturation.
We are unsure why FadD17A1 does not prefer small chain fatty acids, if docking is contributing
to activity, but suspect that since these enzymes are involved in modulating lipid synthesis, more
hydrophobic fatty acids are utilized for construction of methyl-branched lipids and have
precedence over small chain fatty acids.
Activity testing conducted with FadD19A1 demonstrates comparable results, but with
slight preference for C12S mid-chain fatty acids among the saturated substrates tested (Figure 15),
and again weak affinity for small and long chain saturated fatty acids as was seen with FadD17A1.
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Figure 15. Substrate preference of fatty acids for FadD17A1 (top) and FadD19A1
(bottom): Reactions were run with 50 nM of purified recombinant Mtb FadD19A1 or
FadD17A1 and 100 µM of substrate. Reactions were run using the Promega AMP-Glo™
Assay and were quenched at less than 10% conversion, ensuring product formation was less
than 10 µM, established by a linear calibration curve of AMP. Experiment was conducted in
triplicates with three separately purified preparations of proteins. Representative figure of
three biological replicates performed in triplicates.
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When testing unsaturated and polyunsaturated oleic and linoleic acid, a similar trend was seen as
with FadD17A1, but to lesser extent (Figure 15). With FadD17A1, the highest affinity was for
polyunsaturated linoleic acid, even over the mid-chain length saturated fatty acids; but with
FadD19A1 the highest affinity was still for C12S fatty acid. For FadD19A1, unsaturation increased
affinity ~7fold above stearic acid, but activity did not differ between the degrees of unsaturation
as it did with FadD17A1. It must be noted that there does exist a significant difference in substrate
turnover between the two enzymes (Figure 15) when tested at the exact same protein concentration,
determined by a BCA protein quantification kit. These drastic differences in substrate preference
between the two ligases would suggest that FadD19A1 has a definite role in fatty acid catabolism
through b-oxidation mechanisms like its proposed function for steroids.
The results of the activity testing for both fatty acids as well as steroid substrates were
summarized and placed into a table where the values are more easily compared to generate
inferences about substrate specificity (Table 5). Fatty acid testing illustrated the highest activity of
FadD17A1 with linoleic acid (C18-2U) (~56 nM/min) while FadD19A1 preferred lauric acid
(~1049 nM/min). When looking at enzymatic activity towards steroids, the highest activity for
FadD17A1 was with 4-cholenic acid (~1,705 nM/min) while FadD19A1 had highest steroid
activity with the 25-S isomer of 3-oxo-4-cholestenoic acid (~4023 nM/min) (Table 5).

2.3: Discussion
The activity testing completed with FadD17A1, FadD19A1, and FadD19B1 demonstrate
the success of these methods in purifying recombinant proteins utilizing various tags and
elucidating substrate specificity in vitro. In regards to preferred steroid substrates for the above
acyl-CoA ligases, much has been published [1, 49]. The data demonstrated within this section
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Table 5. Substrate preference for steroids and fatty acids of FadD17A1 and FadD19A1:
Table summarizes activity for both enzymes with fatty acids and steroids tested. Activity is
displayed in (nM/min) with standard deviations. Reactions were run using the Promega
AMP-Glo™ Assay and were quenched at 10% conversion, ensuring product formation was
less than 10 µM, established by a linear calibration curve of AMP. Experiment was conducted
in triplicates with three separately purified preparations of proteins.

Molecular
formula
C5H10O2
C6H12O2
C8H16O2
C10H20O2
C11H22O2
C12H24O2
C13H26O2
C14H28O2
C15H30O2
C16H32O2
C17H34O2
C18H36O2
C18H34O2
C18H32O2
C22H30O3
C22H34O3
C24H36O3
C24H38O3
C27H42O3
C27H44O3

Common name
Valeric acid
Caproic acid
Caprylic acid
Capric acid
Undecylic acid
Lauric acid
Tridecylic acid
Myristic acid
Pentadecylic acid
Palmitic acid
Margaric acid
Stearic acid
Oleic acid
Linoleic acid
23,24-Bisnor-Chol-1,4-Dienic acid3-one
23,24-Bisnor-5-Cholenic acid-3β-ol
4-Cholenic acid-3-ONE
5-Cholenic acid-3β-ol
25R-Cholestenoic acid
25S-Cholestenoic acid
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FadD17A1 activity
(nM/min)

FadD19A1 activity
(nM/min)

4.48 ±0.28
6.34 ±0.29
14.47 ±0.39
17.69 ±0.34
22.72 ±0.32
12.71 ±0.36
4.50 ±0.06
3.75 ±0.05
3.98 ±0.08
2.61 ±0.14
2.09 ±0.14
1.77 ±0.00
23.14 ±0.24
56.10 ±0.81

26.11 ±0.64
28.48 ±0.72
46.47 ±0.36
230.68 ±2.42
664.37 ±1.78
1049.67 ±0.21
873.21 ±4.49
784.95 ±2.09
398.42 ±2.61
98.31 ±0.82
388 ±0.27
21.36 ±0.35
170.53 ±0.26
1750 ±0.33

15.16 ±1.03

18.67 ±0.10

17.07 ±1.16
1705.46 ±1.82
1587.26 ±1.05
34.11 ±0.46
235.06 ±0.50

20.23 ±0.08
31.97 ±0.13
29.31 ±0.05
33030 ±6.76
40234 ±4.00

elucidate slight redundancy associated with these enzymes and their ability to turn over all acid
derivatives of cholestenone degradation tested including 23,24-bisnor-chol-1,4-dienic acid (C22),
(23,24-bisnor-5α-cholenic acid-3-one (C22), 5-cholenic acid-3β-ol (C24), 4-cholenic acid-3β-ol
(C24), and the 25-R and 25-S isomers of 3-oxo-4-cholestenoic acid (C27) (Figure 13 and Table
5). Little is known concerning the ligase activity on the C22 steroid, but from this research, we
show that FadD17A1, FadD19A1, as well as FadD19B1 are capable of acting on this substrate in
vitro, albeit with much less affinity than for their preferred C24 and C27 steroids respectively
(Figure 13 and Table 5). Interestingly we have also been able to show that both FadD17A1 and
FadD19A1 have a strong affinity for mid-chain fatty acids and increased activity with longer chain
fatty acids can be accomplished by introducing one and two degrees of unsaturation. FadD17A1
seems to respond more to this mechanism, which can be seen with its overwhelming preference
for linoleic acid over any other fatty acid (Figure 15 and Table 5). Most of the literature
encompassing FadD17A1 and FadD19A1 speculate its importance in cholesterol catabolism, but
very little has been published illustrating its potential catalytic activity associated with fatty acids.
In this work, we successfully elucidate substrate activity between FadD17A1 and FadD19A1
among a wide range of fatty acids as well as the influence of unsaturation on activity (Figure 15
and Table 5) .
When looking at steroid activity more in-depth, our data shows a strong preference for the
25-S isomers of 3-oxo-4-cholestenoic acid (C27) over 25-R isomers of 3-oxo-4-cholestenoic acid
(C27), which is consistent with previous literature (Figure 14) [26, 28]. We were able to show a
stronger affinity at lower concentrations (5µM) for the 25-R isomer of 3b-hydroxy-5-cholestenoic
acid (C27) over the 25-S isomer of 3-oxo-4-cholestenoic acid (C27), but this low concentration
range is followed by an apparent product inhibition range beginning at 10µM that is consistent
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with the bi uni uni bi ping pong mechanism described previously for acetyl-CoA synthetases with
the formation of acetyl-CoA; and this phenomenon could occur by the same mechanism, instead
involving acyl-CoA ligases and the acyl-CoA products illustrated in (Figure 14) [83, 84]. The 25S isomer of 3-oxo-4-cholestenoic acid (C27) seems to be the most stable substrate for activity with
FadD19A1, and continues to undergo turnover even at 100µM, whereas it appears that all other
substrates have resulted in very little product formation at this concentration (Figure 14). We must
also mention a possible solubility issue that may be associated with testing our steroid substrates
at higher concentrations; however, the data show that even at these high concentrations, the 25-S
isomer of 3-oxo-4-cholestenoic acid (C27) seems to have the best substrate specificity and minimal
product inhibition in vitro.
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Chapter 3: Growth, metabolic profiling and activity-based metabolomics
profiling of M. smegmatis DfadD17A2, DfadD19A2, and DfadD19B1
mutant strains in combination with DkstD utilizing various media

3.1: Methods
Deletion of fadD17A2, fadD19A2 and fadD19B1 genes in the model M. smegmatis mc2155
strain
Recombination in Mycobacterium is generally very infrequent and difficult to achieve;
however, a new system for elevating recombination frequencies using phage-encoded proteins
(similar to the E. coli system) has been modified to suit Mycobacterium, and the mechanisms can
be reviewed in [85-89]. The protocol adapted for these experiments closely resembles the protocol
and mechanisms described in [88]. Essentially, M. smegmatis was transformed with pJV53
carrying genes coding for the Che9c protein to generate a recombineering strain. For the
recombineering experiments, cells were first grown in the presence of acetamide to induce the
expression of the recombineering protein and then made electro-competent.

Construction and preparation of allelic exchange substrate (AES):
AES for recombination was produced by amplifying the 5’and 3’ flanking regions (5001,000 bp) of the genes of interest by PCR. For fadD17A2, fadD19A2, and fadD19B1 genes, the
PCR-amplified fragments were sub-cloned on each side of the loxP-hyg-loxP cassette of
pJSC407/hygromycin. The recombination templates were linearized (which also removes oriE
region of the plasmid from the AES) and then purified after separation by electrophoresis on an
agarose gel.
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Purified AES from above was introduced by electroporation into the M. smegmatis strain
expressing the recombineering protein Che9c. After recovery, cells were plated onto solid agar
media containing 50 µg/mL hygromycin. After 4 days of incubation, colonies were observed and
picked for PCR analysis to confirm deletion of gene(s).

Deletion of kstD gene in DfadD17A2, DfadD19A2 and DfadD19B1 mutant strains in M.
smegmatis MC2155

Construction and preparation of allelic exchange substrate (AES):
AES for recombination was produced by amplifying the 5’ and 3’ flanking regions of the
genes of interest by PCR. The PCR fragments were sub-cloned on each side of the loxP-ble-loxP
cassette of pMSG360/zeomycin. The recombination templates were linearized (which also
removes the oriE region of the plasmid from the AES) and then purified after separation by
electrophoresis on an agarose gel.
Purified AES from above was introduced by electroporation into the M. smegmatis fadD
mutant strains from above, after confirmation, also expressing the recombineering protein Che9c.
After recovery, cells were plated onto solid agar media containing 50 µg/mL zeomycin. After 4
days of incubation, colonies were observed and picked for PCR analysis to confirm deletion of
gene.

Growth of M. smegmatis DkstD/fadD mutants with glycerol as sole carbon source:
Before exposing the deletion mutant strains to simpler media, cells were pre-cultured first
in supplemented 7H9 medium containing 10% ADS (v/v), 0.2% glycerol (v/v), 0.5%
50

Tyloxapol/ethanol (v/v) at 37oC and shaking at 200 RPM. After initial growth in rich medium,
cultures were “starved” for two days in 7H9 medium supplemented with only 0.2% glycerol (v/v),
0.5% Tyloxapol/ethanol (v/v) to ensure all other carbon storage had been exhausted. After two
days, culture was used to inoculate 250 mL flasks containing 50 mL 7H9, supplemented with 0.2%
glycerol (v/v), 0.5% Tyloxapol/ethanol (v/v) as a sole source of carbon, at an OD600nm of 0.1.
Tyloxapol, a non-hydrolyzable detergent, was made at 50% with ethanol to ensure sterility.

Growth of M. smegmatis ΔkstD/fadD mutants with cholest-4-en-3-one as carbon source:
Before exposing the deletion mutant strains to cholest-4-en-3-one, cells were pre-cultured
first in supplemented 7H9 medium containing 10% ADS (v/v), 0.2% glycerol (v/v), 0.5%
Tyloxapol/ethanol (v/v) at 37oC and shaking at 200 RPM. After initial growth in rich medium,
cultures were “starved” for two days in 7H9 medium supplemented with only 0.2% glycerol (v/v),
0.5% tyloxapol/ethanol (v/v) to ensure all other carbon storage had been exhausted. After two
days, culture was used to inoculate 250 mL flasks containing 50 mL 7H9, supplemented with 0.2%
glycerol (v/v), 1 mM cholest-4-en-3-one, 0.5% Tyloxapol/ethanol (v/v), at an OD600nm of 0.1.
Cholest-4-en-3-one was dissolved in Tyloxapol, a non-hydrolyzable detergent, made at 50% with
ethanol to ensure sterility. Culture samples (6 mL) were collected in duplicates at 0, 12, 24, and
48 h for extraction of metabolites.

Extraction of metabolites for M. smegmatis MC2155 strains grown with 1 mM cholest-4-en3-one:
At each time point, 6 mL of cultures was transferred into 15 mL glass tubes containing 6
mL of pure ethyl acetate. For quantification of metabolites, 20 µM of 5-cholesten-3β-ol-7-one

51

(Steraloids) was spiked as an internal standard. After gentle mixing and incubation overnight at
4oC, the organic phase containing the cholest-4-en-3-one-derived metabolites was separated by
centrifugation and transferred into clean glass tubes and dried under a stream of nitrogen gas to
proceed with cleaning/desalting and removal of detergent.

Cleaning of metabolite extracts and removal of detergent in M. smegmatis:
Cultures grown with very high concentrations of steroids required a high percentage of
Tyloxapol to aid in solubility. The below-mentioned protocol was useful in removing tyloxapol by
forming a complex that can be separated from metabolite fractions through centrifugation. Excess
detergent from extracts was removed using the cobalt-thiocyanate reagent and back-extraction
with hexane, as described previously [90, 91]. Tyloxapol, due to its sticky nature, was present at
minimal concentrations even after cleaning with cobalt-thiocyanate. Residual Tyloxapol still
remaining after one round of cleaning was minimized further during the desalting procedure with
hexane/acidified water (0.01% (v/v) hydrochloric acid) washes followed by drying down under a
stream of nitrogen gas, and desiccate was stored at -20°C.

Metabolic profiling utilizing heated electrospray ionization (HESI)-liquid chromatography
mass spectrometry (LC/MS) of deletion strains incubated in the presence of cholest-4-en-3one
Metabolites were analyzed by HESI-LC/MS on a Q-Exactive+ Orbitrap or TSQ-Endura
(Thermo Fisher) mass spectrometer equipped with a HESI source and connected to an Ultimate
3000 RS UHPLC separation system (Dionex). Metabolites were separated by injection onto a
Kinetex C18-2.6 µm, 100Ä, 2.1 × 100 mm column (Phenomenex). The metabolites were eluted
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at a flow rate of 0.5 mL/min (solvent A, 0.1% (v/v) formic acid in LC/MS grade 95% water, 5%
acetonitrile; solvent B, 0.1% (v/v) formic acid in LC/MS grade 95% acetonitrile, 5% water). The
starting gradient at 10% B, was held constant for the first 5 min and then ramped up to 100% B
over 35 min. The flow was maintained at 100% B for 10 min and immediately followed by a blank
injection (acetonitrile) to ensure carryover between injections was not occurring. At the end of the
blank injection, the column was brought back to starting conditions (10% buffer B) and maintained
for 10 min to ensure equilibration before next injection. HESI settings for detection of accumulated
metabolites were fixed in positive mode with static spray voltage at 3500V, sheath gas at 40 (Arb),
auxiliary gas at 15 (Arb), sweep gas at 2 (Arb), 400°C vaporizer temperature and 350°C ion
transfer tube temperature. Full MS scan was carried out on either instrument with a scan range of
150-500 (m/z), with 1,000 scan rate (Da/sec) and a Q1 resolution set to 0.7 (FWHM). Metabolite
peaks (Table 6) were analyzed using Xcalibur processing methods pre-set using standards
(Steraloids) for expected metabolites using a 5 ppm mass standard deviation (QExactive+) or 500
ppm (TSQ Endura). Areas were corrected using 5-cholesten-3β-ol-7-one standard (Steraloids) for
each time point across all strains at that time point.

Activity-Based Metabolomic Profiling assay in M. smegmatis ΔkstD/fadD mutants:
To identify the physiological substrate(s) of Mtb FadD17A1 and FadD19A1, extracts
prepared from M. smegmatis deletion mutant cells cultured in the presence of cholest-4-en-3-one
were used in enzymatic reactions in vitro. Substrates present in the extracts and products formed
after incubation with recombinant enzymes were analyzed by HESI-LC/MS. Briefly, 25 µL of
accumulated metabolites from growth experiments with mutant strains, were dried down under a
stream of nitrogen gas and resuspended in 2 µL of OPTIMA-UHPLC grade dimethyl sulfoxide
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Table 6: Metabolites profiled during metabolic profiling assay for wt and mutant strains in
M. smegmatis: The table above includes structural information, chemical formula, + charged
monoisotopic mass [M+H]+, chemical name as well as nomenclature utilized in this paper (in
green) for simplicity and retention times. Masses were identified with 5 ppm mass standard
deviation (QExactive+) or 500 ppm (TSQ Endura), and areas corrected using 5-cholesten-3β-ol7-one standard. 1Retention time utilizing C18-2.6 µm, 100Ä, 2.1 × 50 mm column (Phenomenex)
at a flow rate of 0.50 mL/min (solvent A, 0.1% (v/v) formic acid in LC/MS grade 95% water, 5%
acetonitrile; solvent B, 0.1% (v/v) formic acid in LC/MS grade 95% acetonitrile, 5% water).
Starting gradient at 30% B was held constant for 1 min and then ramped up to 100% B over 10
min and maintained at 100% B for 5 min. 2Retention time utilizing C18-2.6 µm, 100Ä, 2.1 × 100
mm column (Phenomenex) at a flow rate of 0.50 mL/min (solvent A, 0.1% (v/v) formic acid in
LC/MS grade 95% water, 5% acetonitrile; solvent B, 0.1% (v/v) formic acid in LC/MS grade 95%
acetonitrile, 5% water). Starting gradient at 10% B was held constant for 5 min and then ramped
up to 100% B over 35 min and maintained at 100% B for 10 min. ND= not determined in sample,
and no commercial standard available.
Structure

Chemical
formula

[M+H]

+

Name

Retention
time
(mins)
4.21
6.92

C22H32O3

345.2424

23,24Bisnor-4cholenic
acid
(4-BNC)

C23H34O3

359.2581

(4-BNC22OOMe)

ND1
13.02

C18H28O5

325.2010

(CD22OOMe)

ND1
6.32

C24H36O3

373.2737

4-cholenic
acid
(4-C)

6.31
12.62

C25H38O3

387.2894

(4-C24OOMe)

ND1
18.22
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(CD24OOMe)

ND1
12.32

C20H32O5

353.2323

C27H42O3

Cholestenoic
415.3207 Acid 25R/S
(4-CHOL)

C28H44O3

429.3363

(4-CHOL26OOMe)

10.31
23.22

C29H46O3

443.3520

(4-CHOL26OOEt)

10.91
24.62

C23H38O5

395.2792

(CD26OOMe)

7.61
16.82

27-hydroxy4-cholesten3-one

8.81
19.52

8.21
17.62

C27H44O2

401.3414

C27H44O

385.3465

4-cholesten3-one

12.81
ND2

C27H44O2

401.3414

7-ketocholesterol

10.31
23.32
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(Thermo Fisher). Reaction mixtures (100 µL) contained all necessary co-factors and buffers to
perform acyl-CoA ligase activity-based testing with our purified recombinant enzymes (250 nM)
(Table 4). Once all components of reaction were combined, reactions were incubated at 25°C for
varying time points and quenched with (50 µL) of methanol with 0.1% ammonium hydroxide (v/v)
and centrifuged at max speed in the cold to precipitate protein and salts. 25 µL of the reaction was
injected onto a Kinetex EVO C18-2.6 µm, 100 Å, 2.1 × 50 mm column (Phenomenex). Products
were eluted at a flow rate of 0.5 mL/min (solvent A, 0.1% (v/v) ammonium hydroxide in LC/MS
grade 95% - 5 mM ammonium acetate, 5% acetonitrile; solvent B, LC/MS grade 95% acetonitrile,
5% - 5 mM ammonium acetate (buffer A)). The starting gradient at 100% A was held constant for
the first 1 min and then ramped up to 40% B over 25 min. The gradient was further increased to
100% buffer B very quickly in 1 min and maintained at 100% B for 4 min, immediately followed
by a blank injection (methanol) to ensure carryover between injections was not occurring. At the
end of the blank injection, the column was brought back to starting conditions (100% buffer A)
for 20 min to ensure equilibration for next injection. HESI settings for detection were fixed in
positive mode with spray voltage at 3,500 V, sheath gas at 50 (Arb), auxiliary gas at 5 (Arb), 250°C
vaporizer temperature, 200°C ion transfer tube temperature, CID gas at 1.5 mTorr and 38V of
collision energy. SRM scan was utilized with a scan range of 800-1200 (m/z), with 1 s cycle time,
a Q1 resolution of 0.7 (FWHM) and a Q3 resolution of 0.7 (FWHM). SRM mode was carried out
using a precursor and product ion scan which was set to the full mass of the acyl or fatty acid-CoA
as the precursor trigger, and the loss of 507 m/z upon fragmentation which is characteristic of the
fragmentation of CoA from the parent molecule [92]. Metabolite peaks were exported and
analyzed using Xcalibur processing methods identical to those described previously.

56

Growth of M. smegmatis ΔkstD/fadD mutants with glycerol in acetone as sole carbon source:
Before exposing the deletion mutant strains to simple media, cells were pre-cultured first
in supplemented 7H9 medium containing 10% ADS (v/v), 0.2% glycerol (v/v), 0.5%
Tyloxapol/acetone (v/v) at 37oC and shaking at 200 RPM. After initial growth in rich medium,
cultures were “starved” for two days in 7H9 medium supplemented with only 0.2% glycerol (v/v),
0.5% Tyloxapol/acetone (v/v) to ensure all other carbon storage had been exhausted. After two
days, culture was used to inoculate 250 mL flasks containing 50 mL 7H9, supplemented with 0.2%
glycerol (v/v) as a sole source of carbon, 0.5% Tyloxapol/acetone (v/v), at an OD600nm of 0.1.
Tyloxapol, a non-hydrolyzable detergent, was made at 50% with acetone to ensure sterility. 200proof ethanol was spiked into cultures at 48 h at a final concentration of 0.5% (v/v).

Growth of M. smegmatis ΔkstD/fadD mutants with cholest-4-en-3-one in acetone as carbon
source:
Before exposing the deletion mutant strains to cholest-4-en-3-one, cells were pre-cultured
first in supplemented 7H9 medium containing 10% ADS (v/v), 0.2% glycerol (v/v), 0.5%
Tyloxapol/acetone (v/v) at 37oC and shaking at 200 RPM. After initial growth in rich medium,
cultures were “starved” for two days in 7H9 medium supplemented with only 0.2% glycerol (v/v),
0.5% Tyloxapol/acetone (v/v) to ensure all other carbon storage had been exhausted. After two
days, culture was used to inoculate 250 mL flasks containing 50 mL 7H9, supplemented with 0.2%
glycerol (v/v), 1 mM cholest-4-en-3-one, 0.5% Tyloxapol/acetone (v/v), at an OD600 of 0.1.
Cholest-4-en-3-one was dissolved in Tyloxapol, a non-hydrolyzable detergent made at 50% with
acetone to ensure sterility. 200-proof ethanol was spiked into cultures at 48 h at a final
concentration of 0.5% (v/v).
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Quantification of cholest-4-en-3-one in mutant strains grown with cholest-4-en-3-one in
acetone utilizing Charged Aerosol Detection (CAD):
Extracts were analyzed by (CAD) on a Corona Veo RS (Thermo Fisher) connected to an
Ultimate 3000 RS UHPLC separation system (Dionex). Extracts were separated by injection onto
a Kinetex C18-2.6 µm, 100Å, 2.1 × 50 mm column (Phenomenex). Cholest-4-en-3-one was eluted
at a flow rate of 0.5 mL/min (solvent A, 0.1% (v/v) formic acid in LC/MS grade 95% water, 5%
acetonitrile; solvent B, 0.1% (v/v) formic acid in LC/MS grade 95% acetonitrile, 5% water). The
starting gradient at 30% B was held constant for the first 1 min and then ramped up to 100% B
over 6 min. The flow was maintained at 100% B for 8 min and immediately followed by a blank
injection (acetonitrile) to ensure carryover between injections was not occurring. At the end of the
blank injection, the column was brought back to starting conditions (30% buffer B) and maintained
for 10 min to ensure equilibration before next injection. CAD settings for detection of cholest-4en-3-one were fixed in positive mode with data collection rate set at 2 Hz, 5 Hz filter, under
analytical gas regulation mode, evaporator temperature set to 35°C, and a peak width set at 2 min.
Peaks were analyzed and quantified using Chromeleon 7 processing methods pre-set using
standards (Steraloids). Areas were corrected using 5-cholesten-3β-ol-7-one standard (Steraloids)
for each time point across all strains at that time point.
3.2: Results
Mutant strains were successfully created using the above recombination method utilizing
pJV53. For those strains with more than one FadD removed, after the first deletion colonies were
selected and confirmed for removal of 1st gene through PCR, pYO11 was transformed to remove
hygromycin resistance, screened to ensure complete removal of resistance, and the recombination
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method repeated for 2nd and/or 3rd gene removal. An example of the PCR screening process is
provided (Figure 16). This PCR figure illustrates the screening for removal of fadD19A1 in wt as
well as previously obtained mutant strains, DfadD17A2 and DfadD19B1, utilizing primers to
amplify the coding region (P1) as well as primers to amplify the 5’ and 3’ flanking regions (P2
and P3 respectively) (Figure 16 top panel) to ensure only the region of interest was removed
(Figure 16 bottom panel). Once all combinations of mutants were obtained, recombination method
was repeated for removal of kstD, in order to proceed with growth and metabolic profiling.
Growth experiments conducted with mutant strains deficient in expression of FadD
enzymes as well as KstD, were carried out with two different media conditions. Mutant strains
cultured in 7H9, 0.2% glycerol (v/v) showed a very slight growth defect compared to the wt (Figure
17, top). The same starter culture was used to inoculate the same media, except with 1mM cholest4-en-3-one, 0.2% glycerol as the carbon sources, and mutant strains showed an even more
pronounced growth defect when compared to WT (Figure 17, bottom). After extraction and
injection of metabolites obtained from cultures grown in the presence of 1 mM cholest-4-en-3one, we can see detection of 23,24-bisnor-4-cholenic acid (4-BNC), but no significant
accumulation in any of the mutant strains when compared to wt (Figure 18, top). 4-cholenic acid
(4-C) was also detected and most abundant in mutant strain Δkstd/fadD17A2, as expected, but also
accumulated in the Δkstd and Δkstd/fadD19A2 mutants at 48 h (Figure 18, middle). Cholestenoic
acid (4-CHOL) accumulated the most in mutant strain Δkstd/fadD19A2 but also accumulated
significantly in Δkstd and Δkstd/fadD17A2 mutant strains at 48 h (Figure 18, bottom). Methylated
forms of all acid intermediates, 4-BNC-22OOMe, 4-C-24OOMe, and 4-CHOL-26OOMe were
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P1 P2 P3

MSMEG_5913
3’Flanking
(P3)

hyg

R

𝚫fadD19A2
#2

𝚫fadD19A2
#1

wt

5’Flanking
(P2)

𝚫fadD19B1/
19A2 #2
L

𝚫fadD19B1
/19A2 #1

MSMEG_5915
MSMEG_5915

Coding region
(P1)

wt

𝚫fadD17A2
/19A2 #1

wt

L

PCR primers

fadD19A2

L

∆fadD19A2

MSMEG_5913

𝚫fadD17A2/
19A2 #2

WT

P1 P2 P3

P1 P2 P3

Figure 16. Primer design (top) and PCR screening (bottom) to confirm removal of
fadD19A2 in previously obtained mutant strains in M. smegmatis. PCR was performed with
three sets of primers and Phusion High Fidelity DNA Polymerase. PCR reactions were pooled
for consistency among screenings, and each primer added individually.
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Figure 17. Growth of Δkstd mutant strains in M. smegmatis with 7H9, 0.2% glycerol
(v/v) (top) and 7H9, 0.2% glycerol (v/v) with 1 mM cholest-4-en-3-one (bottom).
Growth was carried out for 48 h in 250 mL flasks and was monitored using a 96-well plate
reader. Representative figure of two biological replicates performed in triplicates.
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C22H32O3
[M+H]+=345.2424

C24H36O3
[M+H]+=373.2737

C27H42O3
[M+H]+=415.3207

Figure 18. Metabolic profiling of Δkstd mutant strains in M. smegmatis with 7H9, 1 mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 345 (top), 373 (middle) and 415
(bottom). 6 mL of cell culture was extracted using acidified ethyl acetate overnight at 4°C.
Internal standard, 7-ketocholesterol, was spiked before extraction and cleaning. Quantification
was performed using Xcalibur extraction software on TSQ Endura mass spectrometer.
Statistical significance determined using the Holm-Sidak method, with alpha= 5.00% compared
with wt: (****), P<0.001; (**), P<0.01; (*), P<0.05. Representative figure of two biological
replicates performed in duplicates.
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detected and accumulated in all mutant strains compared to WT (Figure 19). Interestingly, 4CHOL-26OOEt was the only ethylated intermediate detected, and accumulated among all mutant
strains when compared to wt (Figure 20 top). C and D ring intermediate CD-26OOMe was detected
and lower in all mutant strains compared to wt (Figure 20, bottom) along with CD-24OOMe and
CD-22OOMe (Figure 21). The results indicate that our mutant strains are limited in their ring
opening possibilities, thereby contributing to what appears to be a compensatory mechanism that
is activated when either side-chain and/or ring opening of cholestenone is blocked.
The next goal was to take the metabolic extracts from our mutant strains and perform a
unique activity-based metabolomics assay that employs a synthesis- and label-free approach to
discovering activities resulting from missing genes, with the use of our purified recombinant
FadD17A1 and FadD19A1 from M. smegmatis. To increase activity of detected intermediates with
our proteins, we utilized ΔkstD/fadD17A2 mutant extracts which were incubated with either
purified FadD17A1, FadD19A1, or a combination of both. Detection of products were identified
using SRM mode with a unique fragmentation pattern characteristic to only acyl-CoAs as
described above. The results demonstrated interesting profiles, not only in terms of steroid-CoA
products, but fatty acyl-CoAs as well. The main fatty acyl-CoAs detected were nonanoyl-CoA
(C9), decanoyl-CoA (C10), lauryl-CoA (C12), myristoyl-CoA (C14), palmitoyl-CoA (C16) and
oleoyl-CoA (C18U) (Figure 22). Peculiarly, decanoyl-CoA seemed to be detectable over all other
fatty acyl-CoAs regardless of incubation with either FadD17A1, FadD19A1 or both enzymes
(Figure 22). A very similar profile can be observed among all three panels, with the main difference
being the increased production of palmitoyl-CoA (C16) and oleoyl-CoA (C18U) in the presence
of FadD19A1 over FadD17A1 (Figure 22). Profiling observed with production of steroid-CoAs
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C23H34O3
[M+H]+=359.2581

C25H38O3
[M+H]+=387.2894

C28H44O3
[M+H]+=429.3363

Figure 19. Metabolic profiling of Δkstd mutant strains in M. smegmatis with 7H9, 1 mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 359 (top), 387 (middle) and 429
(bottom). 6 mL of cell culture was extracted using acidified ethyl acetate overnight at 4°C.
Internal standard, 7-ketocholesterol, was spiked before extraction and cleaning. Quantification
was performed using Xcalibur extraction software on TSQ Endura mass spectrometer.
Statistical significance determined using the Holm-Sidak method, with alpha= 5.00% compared
with wt: (**), P<0.01; (*), P<0.05. Representative figure of two biological replicates performed
in duplicates.
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C29H46O3
[M+H]+=443.3520

C23H38O5
[M+H]+=395.2792

Figure 20. Metabolic profiling of Δkstd mutant strains in M. smegmatis with 7H9, 1 mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 443 (top), and 395 (bottom). 6 mL
of cell culture was extracted using acidified ethyl acetate overnight at 4°C. Internal standard,
7-ketocholesterol, was spiked before extraction and cleaning. Quantification was performed
using Xcalibur extraction software on TSQ Endura mass spectrometer. Representative figure
of two biological replicates performed in duplicates.
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C18H28O5
[M+H]+=325.2010

C20H32O5
[M+H]+=353.2323

Figure 21. Metabolic profiling of Δkstd mutant strains in M. smegmatis with 7H9, 1 mM
cholest-4-en-3-one 0.5% tyloxapol/ethanol for [M+H]+ 325 (top), and 353 (bottom). 6 mL
of cell culture was extracted using acidified ethyl acetate overnight at 4°C. Internal standard,
7-ketocholesterol, was spiked before extraction and cleaning. Quantification was performed
using Xcalibur extraction software on TSQ Endura mass spectrometer. Statistical significance
determined using the Holm-Sidak method, with alpha= 500% compared with wt: (*), P<0.05.
Representative figure of two biological replicates performed in duplicates.
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Figure 22. Activity-based metabolic profiling assay of Δkstd/fadD17A2 mutant strain with
FadD17A1 (top), FadD19A1 (middle), or co-incubation with both (bottom). 25 µL of
metabolic extract was incubated with 250 nM enzyme, incubated for various time points, and run
using SRM mode on the TSQ Endura mass spectrometer. Representative figure of one biological
replicate.
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demonstrated production of only 4-cholenoyl-CoA (C24) and cholestenoyl-CoA (C27) (Figure
23). As expected, production of 4-cholenoyl-CoA (C24) was most abundant when extract was
incubated with recombinant FadD17A1 but was detected at low levels after 40 min when incubated
with FadD19A1 (Figure 23 top and middle). Similarly, production of cholestenoyl-CoA (C27) was
most abundant in extract incubated in the presence of FadD19A1 but was also detected at low
levels after 40 min when incubated with FadD17A1 (Figure 23 top and middle). Interestingly, a
synergism is apparent with the production of both 4-cholenoyl-CoA (C24) and cholestenoyl-CoA
(C27) when extract is incubated in the presence of both FadD17A1 and FadD19A1 (Figure 23
bottom).
Lastly, preliminary growth studies were monitored in media identical to the previous
conditions, with an exception for the preparation of tyloxapol. Because of the appearance of
esterified intermediates, ethanol was removed from tyloxapol which was instead sterilized using
acetone. Interestingly, a major growth defect was observed for all mutant strains deficient in KstD
that was not rescuable until the addition of 0.5% (v/v) of absolute ethanol into culture medium at
48h for both medias with and without cholest-4-en-3-one (Appendix A-B). After the addition of
absolute ethanol, mutant strains were able to compensate growth up to levels observed with all
other strains, including wt, in 7H9 media, 0.2% glycerol (Appendix A). Mutant strains grown in
the presence of 1 mM cholest-4-en-3-one not only recovered growth after the addition of 0.5%
(v/v) of absolute ethanol, but appeared to grow 3-fold more than other strains, with no initial
growth defect, and plateaued at an OD600nm greater than 3, compared to OD600nm of 1 observed with
other strains in this media (Appendix B). It should be noted that the ΔfadD19A2 and
Δkstd/fadD19A2 mutant strain had not been achieved when this experiment was conducted and is
therefore not included in the current growth profiling or cholest-4-en-3-one quantification when
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Figure 23. Steroid activity-based metabolic profiling assay of Δkstd/fadD17A2 mutant
strain with FadD17A1 (top), FadD19A1 (middle), or co-incubation with both (bottom). 25
µL of metabolic extract was incubated with 250 nM enzyme, incubated for various time points,
and run using SRM mode on the TSQ Endura mass spectrometer. Representative figure of one
biological replicate.
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grown in the presence of acetone.
With cholest-4-en-3-one quantified using a CAD equipped with liquid chromatography,
we can see that the detoxification of cholest-4-en-3-one is greatly reduced in ΔkstD as well as
ΔkstD/fadD mutants cultured in the presence of cholest-4-en-3-one solubilized in
tyloxapol/acetone (Appendix C). WT and ΔfadD mutants alone, appear to have completely
detoxified cholest-4-en-3-one by 48 h, while ΔkstD as well as ΔkstD/fadD mutants appear to have
stagnant levels of cholest-4-en-3-one that remain unchanged throughout the experiment (Appendix
C). It must be noted that no initial growth defect was seen with any of these mutants during the
pre-culture when incubated with 7H9 medium containing 10% ADS (v/v), 0.2% glycerol (v/v),
0.5% tyloxapol/acetone (v/v), and growth defect was only observed after “starving” cultures and
inoculating into media with minimal carbon sources (7H9 media, 0.2% glycerol, 0.5%
tyloxapol/acetone (v/v) or 7H9 media, 0.2% glycerol, 1 mM cholest-4-en-3-one, 0.5%
Tyloxapol/acetone (v/v)). It must also be noted that samples were only extracted until 90 h had
elapsed, whereas the growth of these mutant strains began recovering around 96 h, after the
addition of ethanol at 48 h (Appendix C); and cholest-4-en-3-one levels would have probably
continued to go down had samples been extracted and analyzed by CAD after 90 h.
3.3: Discussion
The results presented in this chapter elucidate what appears to be a compensatory
mechanisms involving esterification possibilities as well as subsequent opening of rings A and B,
allowing for continued degradation of cholest-4-en-3-one when the sidechain degradation is
blocked. As expected, accumulation of 4-CHOL and 4-C were detected in mutant strains deficient
for kstD/fadD19A2 and kstD/fadD17A2 respectively, however 4-BNC did not accumulate in any
of the mutant strains (Figure 18). Deletion of kstD, in combination with our ΔfadD mutants, limits
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the catalysis and elimination of the C-1 and C-2 hydrogen atoms of the A-ring from the polycyclic
ring structure of 3-ketosteroids, resulting in accumulation of methylated 4-BNC-22OOMe, 4-C24OOMe and 4-CHOL-26OOMe when compared to wt (Figure 19). 4-CHOL-26OOEt was the
only ethylated metabolite profiled in this set (Figure 20 top), indicating that ethylated forms of 4BNC and 4-C are not as common in M. smegmatis. Supporting our compensatory mechanism
hypothesis, detection of methylated C and D ring intermediates was lower in mutant strains
deficient in kstD/fadD for CD-22OOMe, CD-24OOMe (Figure 21) and CD-26OOMe compared
to wt (Figure 20, bottom). These results together strongly support the compensatory mechanisms
detailed in this work and elucidate additional steps in the cholesterol degradation pathway that
were not initially characterized. The profiling data, utilizing fadD mutant strains without
expression of KstD, illuminate the robustness of Mycobacterium and their ability to compensate
for the blockade of both cholesterol ring and side chain degradation, achieving uninterrupted
degradation of cholesterol despite such interventions. For these compensatory mechanisms to
occur, it is predicted that cholestenoic acid must first be produced from cholest-4-en-3-one
(cytochrome P450 enzymes) to provide a precursor that will then be esterified with the addition of
either a methyl or ethyl group onto the end of the sidechain, signaling for initiation of the opening
of rings A and B. Through this mechanism, cholesterol can continue to be degraded; however,
effects on lipid production, especially with the limited capacity for production of propionyl-CoA
once rings A and B are opened, are predicted to impact lipid regulation and alter production of
precursors necessary for incorporation into methyl-branched lipids, which is a necessity for
virulence of Mtb [93-97]. Profiling of fadD mutant strains with normal expression of KstD, will
be able to confirm these mechanisms as well as the essential precursors needed to activate this
compensatory pathway.
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Utilization of a unique activity-based metabolomics assay allowed us to visualize
production of both fatty acid-CoAs as well as steroid-CoAs through the incubation of metabolic
extracts from ΔkstD/fadD17A2 mutants with purified recombinant FadD17A1 and FadD19A1, to
confirm physiological substrates of these enzymes as well as confirm activity data presented in
Chapter 2. Interestingly, production of decanoyl-CoA and palmitoyl-CoA seemed to be the most
abundant fatty acyl-CoAs produced regardless of incubation with either FadD17A1 or FadD19A1
(Figure 22). These data, together with those in Chapter 2, confirm a definite role of both acyl-CoA
ligases and their interaction with fatty acids. Detection of 4-cholenoyl-CoA (C24) as well as
cholestenoyl-CoA (C27) confirm specificity of both FadD17A1 and FadD19A1, respectively
(Figure 23). Remarkably, a synergism is observed for production of both 4-cholenoyl-CoA (C24)
as well as cholestenoyl-CoA when extracts are co-incubated with both ligases (Figure 23 bottom).
These data suggest a complementary interaction between the two proteins, allowing for faster
catalytic activity, which has not been previously characterized.
In an attempt to understand where esterified precursors were coming from to allow
production of 4-BNC-22OOMe, 4-C-24OOMe, 4-CHOL-26OOMe and 4-CHOL-26OOEt,
cultures were grown in media identical to that used in the profiling conducted in Figure 17, but
tyloxapol was resuspended in acetone instead of ethanol. Interestingly, a major growth defect was
observed for all ΔkstD mutants with or without the presence of cholest-4-en-3-one (Appendix AB). Upon addition of 0.5% (v/v) of ethanol at 48 h into cultures, ΔkstD and ΔkstD/fadD mutants
began to grow at around 96 h, indicating a rescue of toxicity observed upon the addition of ethanol
into the cultures (Appendix A-B). The mutants cultured in the presence of cholest-4-en-3-one with
a growth defect had growth 3-fold higher than the WT and other mutants not showing an initial
growth defect in this media after the spiking of ethanol. The 3-fold growth increase over the WT
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and other mutants, we suspect, could be due to changes in phenotypes of the cell resulting from
altered lipid production causing cells to be either “skinnier” or “fatter” and contributing to the
differences in optical density of the cultures. It must be noted that the toxicity is not coming from
acetone directly since the pre-culture of all strains cultured with 7H9 medium containing 10%
ADS (v/v), 0.2% glycerol (v/v), 0.5% tyloxapol/acetone (v/v), including ΔkstD mutants, resulted
in no growth defect when compared to the WT and other mutant strains (data not shown). Cholest4-en-3-one quantification of this experiment demonstrated that ΔkstD mutants were severely
deficient in the ability to detoxify cholest-4-en-3-one when grown in the presence of acetone
(Appendix C). Quantification demonstrated that WT and mutant strains with normal expression of
KstD had completely utilized cholest-4-en-3-one by 48 h while ΔkstD mutants had stagnant levels
of cholest-4-en-3-one quantification that remained unchanged through 90 h (Appendix C). Had
extraction been carried out past 90 h, the addition of ethanol at 48 h would have showed increased
detoxification of cholest-4-en-3-one in the ΔkstD mutants, since growth did not recover until
around 96 h (Appendix B). These results would suggest an interaction of the ethanol used to
solubilize tyloxapol with M. smegmatis by providing a pool of precursors available to esterify the
end of the side chain of 4-C, 4-BNC and especially 4-CHOL which we suspect is one of the main
branching points for the proposed compensatory mechanisms illustrated in this body of work.
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Chapter 4: Growth and metabolic profiling of M. smegmatis fadD17A2,
fadD19A2and fadD19B1 mutant strains utilizing various media

4.1: Methods

Growth of M. smegmatis with cholest-4-en-3-one as carbon source:
Before exposing the fadD deletion mutant strains to cholest-4-en-3-one, cells were precultured in supplemented 7H9 medium containing 10% ADS (v/v), 0.2% glycerol (v/v), 0.5%
tyloxapol/ethanol (v/v) at 37oC and shaking at 200 RPM. After initial growth in rich medium,
cultures were “starved” for two days in 7H9 medium supplemented with only 0.2% glycerol (v/v),
0.5% tyloxapol/ethanol (v/v) to ensure all other carbon storage has been exhausted. After two days,
1 mL of cells were used to inoculate 60 mL ink bottles containing 24 mL of 7H9, supplemented
with 1 mM cholest-4-en-3-one, 0.2% glycerol (v/v), 0.5% tyloxapol/ethanol (v/v), at an OD600nm
of 0.05. Cholest-4-en-3-one was dissolved in tyloxapol, a non-hydrolyzable detergent made at
50% with absolute ethanol to ensure sterility. Culture samples (1 mL) were collected in duplicates
at 0, 12, 24, 48 and 72 h for extraction of metabolites.

Growth of M. smegmatis with cholest-4-en-3-one, glucose, Tween-80 media:
Cells were pre-cultured in supplemented 7H9 medium containing 10% ADS (v/v), 0.2%
glucose (v/v), 0.2% glycerol (v/v), 05% Tween-80 (v/v) at 37oC and shaking at 200 RPM. After
initial growth in rich medium, cultures were continued for two days in 7H9 medium supplemented
with 0.2% glycerol (v/v), 0.2% glucose (v/v), 05% Tween-80 (v/v) to ensure all other carbon
storage had been exhausted. After two days, 1 mL of cells were used to inoculate 60 mL ink bottles
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containing 24 mL of 7H9, supplemented with 0.2% glycerol (v/v), 0.2% glucose (v/v), 05%
Tween-80 (v/v), 0.45% ethanol (v/v), 0.5 mM cholest-4-en-3-one, at an OD600nm of 0.05. Cholest4-en-3-one was dissolved in Tween-80/ethanol, to ensure sterility and solubility.

Extraction of metabolites for M. smegmatis mc2155 strains grown with 1.0 mM cholest-4-en3-one:
At each time point, 1 mL of culture were transferred into 15-mL glass tubes containing 1
mL of pure ethyl acetate (acidified by the addition of 0.01% (v/v) hydrochloric acid). For
quantification of metabolites, 20 µM of 5-cholesten-3β-ol-7-one (Steraloids) was spiked as an
internal standard. After gentle mixing and incubation overnight at 4o C, the organic phase
containing the cholest-4-en-3-one-derived metabolites were separated by centrifugation,
transferred into clean glass tubes and dried under a stream of nitrogen gas to proceed with
cleaning/desalting and removal of detergent.

Cleaning of metabolite extracts and removal of detergent in M. smegmatis:
Cultures grown with very high concentrations of steroids require a high percentage of
tyloxapol/Tween-80 to aid in solubility. The below-mentioned protocol was useful in removing
Tween-80 and tyloxapol by forming a complex that can be separated from metabolite fractions
through centrifugation. Excess detergent from extracts was removed using the cobalt-thiocyanate
reagent and back-extraction with hexane, as described previously [90, 91]. Tyloxapol, due to its
sticky nature, will still be present at minimal concentrations even after cleaning with cobaltthiocyanate. Residual tyloxapol still remaining after one round of cleaning was minimized further
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along with desalting through hexane/water washes followed by drying down under a stream of
nitrogen gas, and desiccate was stored at -20°C.

Metabolic profiling utilizing heated electrospray ionization (HESI)-liquid chromatography
mass spectrometry (LC/MS) of deletion strains incubated in the presence of cholest-4-en-3one
Metabolites were analyzed by HESI-LC/MS on a Q-Exactive+ Orbitrap (exact mass
confirmation) and TSQ-Endura (peak quantification) (Thermo Fisher) mass spectrometer
equipped with a HESI source and connected to an Ultimate 3000 RS UHPLC separation system
(Dionex). Metabolites were separated by injection onto a Kinetex C18-2.6 µm, 100Ä, 2.1 × 50
mm column (Phenomenex). The metabolites were eluted at a flow rate of 0.50 mL/min (solvent
A, 0.1% (v/v) formic acid in LC/MS grade 95% water, 5% acetonitrile; solvent B, 0.1% (v/v)
formic acid in LC/MS grade 95% acetonitrile, 5% water). The starting gradient at 30% B was held
constant for the first 1 min and then ramped up to 100% B over 10 min. The flow was maintained
at 100% B for 5 min and immediately followed by a blank injection (acetonitrile) to ensure
carryover between injections is not occurring. At the end of the blank injection, the column was
brought back to starting conditions (30% buffer B) and maintained for 10 min to ensure
equilibration before next injection. HESI settings for detection of accumulated metabolites were
fixed in positive mode with static spray voltage at 3500V, sheath gas at 40 (Arb), auxiliary gas at
15 (Arb), sweep gas at 2 (Arb), 400°C vaporizer temperature and 350°C ion transfer tube
temperature. A full MS scan was carried out on either instrument with a scan range of 150-500
(m/z), with 1000 scan rate (Da/sec) and a Q1 resolution set to 0.7 (FWHM). Metabolite peaks
(Table 6) were analyzed using Xcalibur processing methods pre-set using standards (Steraloids)
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for expected metabolites using a 5 ppm mass standard deviation (QExactive+) or 500 ppm (TSQ
Endura). Areas were corrected using 5-cholesten-3β-ol-7-one standard (Steraloids) for each time
point across all strains at that time point.

Transformation of mutant strains with firefly luciferase reporter construct
To create a firefly luciferase reporter construct responsive to intracellular levels of
propionate, the promoter region of the prpR gene (Rv) was amplified by PCR. The amplicon was
used to replace the G13 promoter of the integrative plasmid pMV306DIG13 + FFlucRT (a
gift from Brian Robertson (Addgene plasmid # 49998)) by digesting both the amplicon and the
plasmid with NotI and EcoRI to generate pMV306DIprpR + FFlucRT. The plasmid was
introduced in M. smegmatis as well as DfadD17A2, DfadD19A2, DfadD17A2/fadD19A2 and
DfadD17A2/fadD19A2/fadD19B1 mutant strains. Preliminary assays revealed weak luminescence,
compared with that obtained from cells transformed with pMV306DIG13 + FFlucRT. To increase
sensitivity, the prpR-FFlucRT cassette was digested with NotI and XbaI and sub cloned into the
replicative plasmid pMV261zeo to generate pMV261zeo/prpR-FFlucRT which was transformed
again into the above mentioned strains in M. smegmatis.
Growth of mutant strains and luciferase analysis
Transformants were tested for luciferase activity in triplicates after growth in 7H9 media
containing 0.2% (v/v) glycerol medium supplemented with either 0.25 mM 5-cholenic, 5
mM sodium acetate, 50 µG/mL stearic acid, 0.25 mM cholest-4-en-3-one or 5 mM sodium
propionate at 37oC and shaking at 100 RPM in white 96-well plates. The luciferase activity was
measured using a Luminoskan Ascent plate reader (Labsystems) upon addition of D-luciferin (150
µg/mL) to cells.
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Acid fast staining of M. smegmatis and mutant strains
A loop full of M. smegmatis and DfadD17A2, DfadD19A2, DfadD19A2/fadD19B1,
DfadD17A2/fadD19A2 and DfadD17A2/fadD19A2/fadD19B1 mutant strains obtained at 48 h from
growth profiling in 7H9, supplemented with 0.2% glycerol (v/v), 0.2% glucose (v/v), 05% Tween80 (v/v), 0.45% ethanol (v/v), 0.5 mM cholest-4-en-3-one were heat fixed on slides at 80ºC for 15
min. After smears were fixed, staining was initiated by placing slides on a grate apparatus set over
a water bath with a pre-cut filter paper measuring the same dimensions as the slides. Carbol fuchsin
(Presque Isle) was placed on the filter paper and allowed to stain the cells on the slide with the aid
of the steam for 5 min ensuring the filter paper did not dry out. After the 5 min, the slides were
rinsed with water, followed by 15 s rinse in acid alcohol (Presque Isle) and again rinsed with water.
Methylene blue (Presque Isle) was then placed on the slides and left to counterstain for 1 min, and
again rinsed with water. Slides were dried and immediately imaged at 40X using a DMi1 inverted
microscope (LEICA) utilizing LAS-EZ software provided.

4.2: Results
The first growth profile conducted was carried out in very minimal media (in terms of
carbon sources) - 7H9 media containing 0.2% glycerol (v/v), 1mM cholest-4-en-3-one and 0.5%
tyloxapol/ethanol as the surfactant. When looking at the figure no dramatic growth defect was
detected. The mutant strain deficient for fadD19A2 alone seemed to have a slight growth defect
versus all other strains (Figure 24). A slight growth delay at the start of the experiment can be
observed and is attributed to the high concentration of cholest-4-en-3-one in the media, which is
known to be toxic to Mycobacterium [26, 28].
Growth profiling of these mutant strains was then repeated using a media with multiple
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Figure 24. Growth of mutant strains in M. smegmatis with 7H9, 0.2% glycerol (v/v), 1mM
cholest-4-en-3-one, 0.5% tyloxapol/ethanol (v/v). Growth was carried out for 96 h in 60 mL
ink bottles and was monitored using a 96-well plate reader. Graph is a representation of three
biological replicates performed in triplicates.
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carbon sources, which had been suggested at a conference at which observations were reported
that media containing multiple carbon sources present more stress on the bacteria when grown in
the presence of cholest-4-en-3-one. For this experiment we carried out growth with the same media
as above, but in combination with 0.2% glucose, and 0.05% Tween-80 used instead of tyloxapol.
From this experiment we can observe that all the mutant strains display a growth defect after the
log phase of growth (Figure 25). The optical density measurements show a dramatic decrease of
all mutant strains at 48 h compared to WT, as if cells had begun dying; or hinting at induced
differences in cell morphology (Figure 25). It is noted that there were no visible indications of cell
death when looking at the cultures, but instead a visible difference was observed in the texture of
the cells, as well as in the degree of waxy residue left on the containers when grown with shaking
compared to WT (data not shown). These results would suggest that the differences in OD readings
among the mutant strains could indicate a difference in cell morphology – we now believe, with
cells being thinner among mutants - appearing at 48 h (Figure 25). Overall, we can conclude that
there is no significant growth defect, especially during the log phase of growth, among our mutants
regardless of the media used, indicating that no toxic intermediates accumulate to exhibit a
bacteriostatic effect as was observed with CYP125A1 mutations previously [26, 28].
Our next goal was to confirm and quantify metabolites produced from the above growth
profiling experiments. Injection of the metabolites extracted from the strains grown with glucose
and Tween-80 showed very little accumulation of detectable metabolites other than cholest-4-en3-one, 4-CHOL, and our internal standard 7-ketocholesterol (data not shown). We hypothesize
that the presence of multiple carbon sources allows Mycobacterium to degrade cholest-4-en-3-one
with more possibilities of shuttling intermediates into other pathways, limiting accumulation of
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Figure 25. Growth of mutant strains in M. smegmatis with 7H9, 0.2% glycerol (v/v), 0.2%
glucose (v/v), 0.05% Tween-80 (v/v), 0.45% ethanol (v/v), 0.5 mM cholest-4-en-3-one.
Growth was carried out for 96 h in 60 mL ink bottles and was monitored using a 96-well plate
reader. Graph is a representation of three biological replicates performed in triplicates.
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intermediates that ionize and are detectable with the method used. We then injected the metabolites
grown in the presence of 1 mM cholest-4-en-3-one and glycerol only and were able to detect more
intermediates of the cholesterol degradation pathway (Figure 26 and 28). In regards to cholest-4en-3-one degradation, we can see that all strains degrade cholest-4-en-3-one in a similar fashion,
with the exception of the DfadD19A2/fadD19B1 mutant strain which seems to degrade cholest-4en-3-one much quicker than all other strains, explaining its quicker buildup of intermediates
compared to other strains (Figure 26 top). Mutant strains DfadD19A2, DfadD17A2/fadD19A2, and
DfadD17A2/fadD19A2/fadD19B1 are impacted, with slower ability to detoxify cholest-4-en-3-one
after 72 h in comparison with other mutant strains and wt (Figure 26 top). It was observed that in
all mutant strains involving either removal of both fadD17A2 and fadD19A2, or fadD19B1, a
significant accumulation of 27-OH-cholest-4-en-3-one was detected (Figure 26 middle). 4-CHOL
appears to build up in all mutant strains involving removal of fadD19A2, and the highest level of
accumulation can be seen for the DfadD19A2/fadD19B1 mutant strain at 24 h (Figure 26 bottom).
Interestingly, a small accumulation of 4-CHOL is also seen at 24 h in the DfadD17A2 mutant, but
then disappears after 24 h (Figure 26 bottom), and the expected 4-C metabolite does not
accumulate at any time point for DfadD17A2 mutant strain. 4-CHOL-26OOMe and 4-CHOL26OOEt also accumulated in all mutant strains involving removal of fadD19A2 (Figure 27, top
and middle). Again, the highest accumulation of both metabolites can be seen for the
DfadD19A2/fadD19B1 mutant strain at 24 h, and peaks at 48 h for all other mutant strains involving
removal of only fadD19A2. Interestingly, again, we see a statistically significant accumulation of
these products at 24 h in the DfadD17A2 mutant compared to WT (Figure 27, top and middle).
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C27H44O
[M+H]+=385.3465

C27H44O2
[M+H]+=401.3414

C27H42O3
[M+H]+=415.3206

Figure 26. Metabolic profiling of mutant strains in M. smegmatis with 7H9, 0.2%
glycerol, 1 mM cholest-4-en-3-one, 0.5% Tyloxapol/ethanol for [M+H]+ 385 (top), 401
(middle) and 415 (bottom). 1 mL of cell culture was extracted using acidified ethyl acetate
overnight at 4°C. Internal standard, 7-keto cholesterol, was spiked before extraction and
cleaning. Quantification was performed using Xcalibur extraction software on TSQ Endura
mass spectrometer. Statistical significance determined using the Holm-Sidak method, with alpha=
5.00% compared with wt: (***), P<0.001; (**), P<0.01; (*), P<0.05). Graph is a representation
of two biological replicates performed in duplicates.
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C28H44O3
[M+H]+=429.3363

C29H46O3
[M+H]+=443.3520

C23H38O5
[M+H]+=395.2792

Figure 27. Metabolic profiling of mutant strains in M. smegmatis with 7H9, 0.2%
glycerol, 1 mM cholest-4-en-3-one, 0.5% tyloxapol/ethanol for [M+H]+ 429 (top), 443
(middle) and 395 (bottom). 1 mL of cell culture was extracted using acidified ethyl acetate
overnight at 4°C. Internal standard, 7-keto cholesterol, was spiked before extraction and
cleaning. Quantification was performed using Xcalibur extraction software on TSQ Endura
mass spectrometer. Statistical significance determined using the Holm-Sidak method, with
alpha=500% compared with wt: (***), P<0.001; (**), P<0.01; (*), P<0.05). Graph is a
representation of two biological replicates performed in duplicates.
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Our next goal was to determine whether ring opening was occurring more frequently in
these mutant strains, and we were only able to detect the CD ring metabolite CD-26OOMe (Figure
27, bottom). This metabolite is obviously a product resulting after the 429 m/z metabolite is
obtained. Similar trends of accumulation can be seen for this CD ring metabolite as is seen for 4CHOL-26OOMe. The highest accumulation of the CD ring metabolite can be seen for the
DfadD19A2/fadD19B1 mutant strain at 24 h, and peaks at 48 h for all other mutant strains involving
removal of fadD19A2 (although with large variation among replicates at 48 h for
DfadD17A2/fadD19A2, and DfadD17A2/fadD19A2/fadD19B1) (Figure 27, bottom). Mutant
strains involving removal of fadD19A2, including DfadD19A2/fadD19B1, have the highest level
of accumulation compared to all other mutant strains.
Use of the propionate reporter construct, allowed us to visualize differences with
production of propionate when growing M. smegmatis as well as mutant strains in various media
conditions. As expected, measurement of luciferase with cultures grown in the presence of 0.2%
glycerol with and without supplementation of 5 mM sodium acetate lead to very little observable
differences in luciferase activity indicating endogenous propionate levels to be unaffected among
our mutant strains when compared with each other or the wt (Figure 28, top and middle).
Interestingly, growth of our strains in 5 mM sodium propionate led to decreased ability to detoxify
propionate across all mutant strains when compared to WT at 24 and 48 h for sodium propionate
(Figure 28, bottom). Interestingly, cultures grown in the presence of 0.2% glycerol with oleic acid,
resulted in accumulation of propionate at 24 h across all mutant strains (Figure 29, top). Cultures
grown in the presence of 0.2% glycerol with 0.25 mM 5-cholenic led to an interesting increased
production of endogenous propionate at 24 h across all mutant strains followed by a drastic
decreased production at 48 h when compared to WT (Figure 29, middle). Growth in the presence
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Figure 28. Luciferase reads of mutant strains in M. smegmatis transformed with
pMV261zeo/prpR-FFlucRT grown with glycerol (top), acetate (middle) and propionate
(bottom). 50 µL of cell culture was extracted and mixed with 50 µL of D-luciferin (150 µg/mL)
and read in triplicates measuring relative luminescence units. Graph is a representation of one
biological replicate performed in triplicates.
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Figure 29. Luciferase reads of mutant strains in M. smegmatis transformed with
pMV261zeo/prpR-FFlucRT grown with oleic acid (top), 5-cholenic (middle) and cholest4-en-3-one (bottom). 50 µL of cell culture was extracted and mixed with 50 µL of Dluciferin (150 µg/mL) and read measuring relative luminescence units. Graph is a
representation of one biological replicate performed in triplicates.
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of 0.2% glycerol with 0.25 mM cholest-4-en-3-one displayed increased initial propionate
production at 24 h across all mutant strains but an expected decrease of endogenous propionate
production at 48, 72 and 96 h across all mutant strains with the most notable differences in
DfadD17A2 and DfadD17A2/fadD19A2/fadD19B1 mutants (Figure 29, bottom).
The staining of M. smegmatis and our mutant strains led to unique identifications in
suggested differences in lipid composition of the cell wall resulting from our mutations. M.
smegmatis wt staining resulted in the typical bright red/pink staining as well as the clumping
phenotype that is typical of Mycobacterium (Figure 30, panel A). Staining of DfadD17A2,

DfadD17A2/fadD19A2 and DfadD17A2/fadD19A2/fadD19B1 mutants all showed increased
staining with the counterstain, methylene blue, instead of lipid staining with carbol fuchsin and a
very wide spread dispersion of the cells as opposed to the characteristic clumping phenotype, all
suggesting a decrease in lipid content of the cell wall, which is the principle behind the ZiehlNeelsen stain (Figure 30, panels B, E and F). Interestingly, staining of DfadD19A2 mutant showed
cells that had a very bright red/pink staining but an altered phenotype that did not show as much
clumping as the WT (Figure 30, panel C). Lastly, staining of DfadD19A2/fadD19B1 showed a
decrease in absorption of carbol fuchsin and increase absorption of counterstain, but resulted in
cells that still had the characteristic clumpy phenotype (Figure 30, panel D).
4.3: Discussion
The profiling of mutant strains in this section revealed interesting modifications to the
cholesterol degradation pathway that have not been previously characterized. Although it was
discouraging to not obtain any growth defect in mutant strains cultured in the presence of 1 mM
cholest-4-en-3-one (Figure 24), a slight growth deficiency after the log phase was obtained with
all mutants when grown in a more complex media with multiple carbon sources (Figure 25). These
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Figure 30. Ziehl-Neelsen staining of M. smegmatis wt (panel A) and mutant strains
DfadD17A2 (panel B), DfadD19A2 (panel C), DfadD19A2/fadD19B1 (Panel D),
DfadD17A2/fadD19A2 (panel E) and DfadD17A2/fadD19A2/fadD19B1 (panel F): Cells were
cultured in 7H9, 0.2% glycerol, 0.2% glucose, 05% Tween-80, 0.45% ethanol, 0.5 mM cholest4-en-3-one. Cells were harvested at 48 h and re-suspended in PBS. Cells were stained and imaged
using a DMi1 inverted microscope
89

data support the initial hypothesis of this study which suggests important roles for the investigated
FadDs in the reshaping of Mtb’s metabolism from glucose to cholesterol. Physiologically, it is not
realistic that these strains would ever be surrounded by 1 mM of cholest-4-en-3-one solely, but
instead an environment more like that provided in the complex media with multiple carbon sources
presenting more metabolic stress on the cells is more biologically relevant. When looking at the
profiling data, we can see that cholest-4-en-3-one detoxification is affected in all mutants involving
removal of fadD19A2 (Figure 26, top), but a growth defect is not observed (Figure 24). These
results suggest either a redundancy in function for some of the FadDs in M. smegmatis and/or a
compensatory mechanism to limit the accumulation of any toxic intermediates. Accumulation of
4-CHOL confirms a relatively high specificity for FadD19 enzyme with the corresponding
substrate, since all mutant strains involving removal of fadD19A2 let to a significant accumulation
of 4-CHOL (Figure 26 bottom). Interestingly, the DfadD19A2/fadD19B1 mutant strain had the
highest accumulation of 4-CHOL, which seemed to peak at 24 h instead of the 48 h observed for
all the other mutant strains. This trend of faster accumulation of metabolites is observed across all
metabolites quantified, as well as a quicker decrease in cholest-4-en-3-one detected for
DfadD19A2/fadD19B1 mutant strain, indicating the removal of fadD19A2/fadD19B1 leading to an
expedited catabolism of cholest-4-en-3-one over all other mutant strains (Figure 26). These results
indicate that even though FadD19A2 and FadD19B1 share very low sequence homology, the two
proteins are both capable of catabolizing 4-CHOL, given the increased abundance of this
metabolite in the DfadD19A2/fadD19B1mutant compared to DfadD19A2 alone; but also indicate
that the removal of both lead to an increased metabolic rate over all other mutant strains.
Modifications to 4-CHOL, such as esterification of either a methyl or ethyl group, were
one of the most interesting trends we noticed involving all mutant strains. It appears from our data
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that a confirmed compensatory mechanism exists and is activated when the side chain degradation
of cholest-4-en-3-one is blocked. Significant accumulation of both 4-CHOL-26OOMe and 4CHOL-26OOEt was identified in all mutant strains deficient in any combination of the FadD
enzymes (Figure 27 top and middle). After this step, opening of ring A and B also occurred more
frequently in all mutant strains indicating this mechanism occurs after esterification of 4-CHOL
(Figure 27, bottom). This profiling data along with the data of mutant strains also deficient for
KstD, confirm esterification mechanism as well as subsequent opening of rings A and B as the
compensatory mechanisms allowing for the similar growth of our mutant strains compared to the
wt. The lack of accumulation of 4-C in any of the mutant strains, especially in the DfadD17A2,
and DfadD17A2/fadD19A2 mutants, supports this compensatory mechanism since esterification as
well as the opening of ring A and B occurs before FadD19A2 is able to act on 4-CHOL; therefore
the first propionate molecule in the pathway would never actually be produced, nor the resulting
4-C substrate. Increased accumulation, among all mutant strains involving removal of fadD19A2,
of subsequent C and D ring metabolite CD-26OOMe profiled in this section further confirm our
proposed mechanism (Figure 27 bottom). Previous profiling of mutants in which the 3-oxosteroid
1-dehydrogenase gene was also deleted supports these findings since 4-C, 4-BNC as well as their
methylated products 4-C-24OOMe and 4-BNC-22OOMe could only be detected with these
DkstD/fadD mutants. KstD, which is essential for the catalysis and elimination of the C-1 and C-2
hydrogen atoms of the A-ring from the polycyclic ring structure of 3-ketosteroids, appears to be a
major rescue mechanism after esterification of 4-CHOL when side chain is blocked [44, 98].
The unique reporter assay utilized here demonstrated various levels of endogenous
propionate among our mutant strains when compared to WT. Interestingly, one of the most
noticeable differences was when the strains were cultured in the presence of 5 mM sodium
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propionate, all mutant strains showed at least 2-fold or greater propionate levels at 24 and 48 h
compared to WT (Figure 28, bottom). Since propionate was being supplied in the media, this
illustrates a defect in the ability to detoxify propionate and shuttle into lipid synthesis pathways
for all our mutant strains compared to the WT. When grown in the presence of oleic acid, there
was an unexpected ~3-fold increase of propionate production in all mutant strains at 24 h when
compared to wt (Figure 29, top). These results were unexpected in the sense that traditional βoxidation of oleic acid should generate acetyl-CoAs as opposed to any production of propionylCoA. Lastly, strains cultured in the presence of 0.25 mM cholest-4-en-3-one demonstrated an
initial increased production of propionate, but then decreased levels at 48, 72 and 96 h compared
to WT (Figure 29, bottom). These results would suggest that our fadD mutants have indeed been
successful in blocking the side chain degradation which provides more sources of propionate when
uninterrupted, than opening of rings A and B after esterification of 4-CHOL engaged in with the
compensatory mechanisms suggested in this work. The results, altogether, demonstrate a
disruption in production and/or detoxification of propionate among our mutant strains, on more
than one type of media, which is essential for providing pre-cursors for methyl branched lipids
incorporated into the cell wall of all mycobacterium strains, which are particularly essential for
virulence in Mtb.
Staining of our strains with the Ziehl-Neelsen method allows us to visualize differences in
lipid composition of the cell wall. Typically, the phenolic compound, carbol fuchsin, is lipid
soluble and is used to penetrate the characteristic waxy cell wall of Mycobacterium. This process
is done utilizing steam or heat, which aids in melting the wax and allowing the stain to move into
the cell. Organisms that have decreased lipid content, or wax, in the cell wall will be subject to
decolorization during the acid alcohol rinsing and counterstained with the methylene blue.
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Interestingly, all our mutants, except for DfadD19A2 and DfadD19A2/fadD19B1 mutant appear to
have lost their acid fast phenotype, indicating a decreased lipid content in the cell wall (Figure 30
panels B, E and F). Our WT strain stained typical of Mycobacterium, as well as the DfadD19A2
mutant (Figure 30 panels A and C). The DfadD19A2/fadD19B1 mutant had a staining that showed
areas of dense clumping as well as pink/red color, but also displayed more than usual counter
staining with methylene blue that was not seen in the wt (Figure 30 panel D). These results
reinforce the hypothesis of altered endogenous propionate production among our mutants which
subsequently alters the lipid composition of the cell wall in Mycobacterium.
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Chapter 5: Overview and final conclusions
Mycobacterium tuberculosis is a serious health issue arising from the increasing incidence
of multi-drug resistant (MDR-TB) strains that are becoming more prevalent in high-risk countries,
especially here in the Texas/Mexico border. Confirmed cases and outbreaks in schools and
hospitals are more frequent in this region due to the high volume of pedestrian traffic between the
two cities, and the lack of a modernized health system in Mexico. Identification of new Mtb
metabolic pathways for development of novel antitubercular drugs is urgently needed. Evidence
suggests Mtb requires cholesterol for phagocytosis in macrophages and to sustain chronic
infection; however, understanding of these lipid catabolic pathways is limited [26, 28, 29, 37, 5254, 61].
Previous work demonstrated that deletion of cyp125A1, resulted in the bacteria’s inability
to convert cholest-4-en-3-one to cholestenoic acid, and thereby created a bacteriostatic effect on
the growth of Mtb due to the toxicity associated with high levels of cholest-4-en-3-one [26, 28].
The goal of this current work was to investigate two FadD enzymes (FadD17A1 and FadD19A1)
to explore whether removal of these genes could achieve an effect like the one described for
Dcyp125A1. Our initial hypothesis was that the utilization of host cholesterol reshapes Mtb’s
metabolism as an adaptive mechanism for survival in macrophages and that these two acyl-CoA
ligases (FadD17A1 and FadD19A1) play an essential role in the cholesterol degradation process.
Most of the work described in this project involves the utilization of a Mycobacterium smegmatis
model which is very common and frequently used to investigate the role of enzymes with unknown
functions in a much quicker manner due to the rapid growth of M. smegmatis over Mtb.
Regarding FadD19A1, M. smegmatis has two copies of this protein, both sharing
conservation. The primary homologue in M. smegmatis, termed “FadD19A2,” is more closely
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related (86% sequence identity) to FadD19A1 in Mtb than is the second copy of FadD19A1 in M.
smegmatis, termed “FadD19B1” (35% sequence identity) (Figures 6 and 7). Interestingly, most of
the acyl-activating enzyme consensus motif, putative AMP binding site, and putative active site
are conserved among all three versions even with the relatively low sequence identity for
FadD19B1. This sequencing analysis hints at some redundancy in M. smegmatis concerning this
enzyme, but also confirms a relevance of using M. smegmatis as a model for Mtb. FadD17A1 does
not have multiple copies in M. smegmatis (66% sequence identity) (Figure 5), making it an easier
target to investigate in M. smegmatis. Most of this work involves the use of mutant strains to
identify accumulated metabolites when grown in various media conditions, so understanding the
multiple copies of these proteins was essential to ensure a complete knockout was obtained, as was
the case for FadD19A1 studies in M. smegmatis.
Reconstituting enzymatic activities in vitro from purified recombinant FadD19A1 and
FadD17A1 was the first goal of this project, to understand what exactly these proteins are doing.
Previous literature hypothesized their importance in the catabolism of steroids, particularly the
degradation of the side chain with FadD17A1 acting on 4-cholenic acid (C24) and FadD19A1
acting on cholestenoic acid (C27), and said to be essential for degradation of C24 branched sterols
in vivo [1, 49]. Additionally, the role(s) of FadD17A1 and FadD19A1 have been proposed as
catalysis of coenzyme A thioesterification of long-chain fatty acids, but which length of fatty acids
they can act upon and whether there is only one substrate capable of binding with each enzyme to
activate esterification was still unknown. We have been able to show that both FadD17A1 and
FadD19A1 can turn over C5-C18 saturated fatty acids but have a stronger affinity for mid-chain
fatty acids, and increased activity with longer chain fatty acids can be accomplished by introducing
one and two degrees of unsaturation. FadD17A1 seems to respond more to this modification,
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which can be seen with its overwhelming preference for linoleic acid over any other fatty acid
(Figure 15 and Table 5). Here we have been able to show that slight redundancy exists in these
enzymes’ ability to turn over all acid derivatives, produced during cholestenone degradation, tested
including 23,24-bisnor-chol-1,4-dienic acid (C22), (23,24-bisnor-5α-cholenic acid-3-one (C22),
5-cholenic acid-3β-ol (C24), 4-cholenic acid-3β-ol (C24), as well as the 25R and 25S isomers of
3-oxo-4-cholestenoic acid (C27) (Figures 13, 14 and Table 5). The 25S isomer of 3-oxo-4cholestenoic acid (C27) seems to be the best substrate for activity with FadD19A1, while 4cholenic acid (C24) appears to be the best for FadD17A1 (Table 5).
Growth of mutant strains revealed interesting modifications to the cholesterol degradation
pathway that have not been previously characterized. A slight growth deficiency was obtained with
our mutant strains, with normal expression of KstD, after the log phase only when utilizing a more
complex media with multiple carbon sources (Figure 25). These data support the initial hypothesis
of this study which predicts important roles for the FadDs in the reshaping of Mtb’s metabolism
from glucose to cholesterol. Profiling data demonstrated that cholest-4-en-3-one detoxification is
slightly affected in all mutants involving removal of fadD19A2 (Figure 26, top), but a growth
defect was not observed (Figure 24). These results suggest either a redundancy in function for
some of the FadDs in M. smegmatis or a compensatory mechanism to limit the accumulation of
any toxic intermediates. Accumulation of 4-CHOL confirms a relatively high specificity for
FadD19A1, since ΔfadD19A2 and ΔfadD19A2/fadD19B1 mutant strains had the highest
accumulation of 4-CHOL (Figure 26, bottom). These results indicate that, even though FadD19A2
and FadD19B1 share very low sequence homology, the two proteins are both capable of
catabolizing 4-CHOL, given the increased abundance of this metabolite in the above-mentioned
mutants.
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Most interestingly, it appears from our data that a compensatory mechanism exists and is
activated when the side chain degradation of cholest-4-en-3-one is blocked. Significant
accumulation of both 4-CHOL-26OOMe and 4-CHOL-26OOEt was identified in all mutant strains
deficient in any combination of the FadD enzymes (Figures 28, top and middle). After this step,
opening of rings A and B (CD-26OOMe) also occurred more frequently in all mutant strains,
indicating this mechanism occurs after esterification of 4-CHOL (Figure 27, bottom). Our data
indicate esterification mechanisms as well as subsequent opening of rings A and B as
compensatory mechanisms allowing for the similar growth of our mutant strains compared to the
WT (Figure 31).
In order to confirm, a second set of mutants was utilized in which the 3-oxosteroid 1dehydrogenase gene was deleted, coding for KstD, which is essential for the catalysis and
elimination of the C-1 and C-2 hydrogen atoms of the A-ring from the polycyclic ring structure of
3-ketosteroids. Detection of 4-BNC as well as 4-C (Figure 18 top and middle), which was
undetectable in fadD mutant strains with unaltered expression of the 3-oxosteroid 1-dehydrogenase
KstD, confirms the proposed compensatory mechanisms acting before attachment of CoA onto 4CHOL by FadD19A2/FadD19B1 in M. smegmatis. Deletion of kstD, in combination with our fadD
mutants, resulted in increased accumulation of 4-BNC-22OOMe, 4-C-24OOMe and 4-CHOL26OOMe compared to wt, as expected (Figure 19). Finally, detection of CD-22OOMe, CD24OOMe, and CD-26OOMe intermediates was lower in mutant strains deficient for expression of
KstD (Figures 21, bottom and 22). These results together confirm the compensatory mechanisms
and elucidate additional steps in the cholesterol degradation pathway that were not initially
characterized and have been added (Figure 31).
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Figure 31. Modified cholesterol side-chain degradation pathway with compensatory
mechanisms. Degradation pathways are labeled in (purple). Key players FadD17A1 and
FadD19A1 at these steps are labeled in (red). Enzymes in (blue) show activity in vitro with the
substrates but are not the key players at this step. Beginning, ending and important intermediate
substrates involved are labeled in (green).
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Use of a propionate reporter assay demonstrated decreased endogenous levels of
propionate among mutant strains when grown in the presence of cholest-4-en-3-one (Figure 29
bottom), as well as a deficiency in detoxifying propionate directly supplied in the culture medium
among all mutant strains when compared to WT (Figure 28, bottom). Decreased levels of
propionate among the mutant strains when grown in the presence of cholest-4-en-3-one (Figure
29, bottom) supports the compensatory mechanisms proposed in this work since opening of rings
A and B would lead to decreased production of propionyl-CoA versus normal uninterrupted
degradation of the full side chain. Alterations in propionate production subsequently leads to
significant effects in production of methyl-branched lipids which are essential for the characteristic
waxy cell wall in Mycobacterium and even more essential for the virulence of Mtb.
Acid-fast staining of our organisms confirmed differences in lipid composition of the cell
wall resulting from our mutations. Organisms that have decreased lipid content, or wax, in the cell
wall are subject to decolorization during the acid alcohol rinsing and counterstained with
methylene

blue.

Interestingly,

all

our

mutants

except

for

the

ΔfadD19A2

and

ΔfadD19A2/fadD19B1 mutants, appear to have lost their acid-fast phenotype and appear bluer than
pink/red, indicating a decreased lipid content in the cell wall (Figure 30, panels B, E and F). Our
WT strain stained in a manner typical of Mycobacterium, and the ΔfadD19A2 mutant retained the
carbol fuchsin but displayed less of a clumping phenotype than the WT (Figure 30, panels A and
C, respectively). The ΔfadD19A2/fadD19B1 mutant had a staining that showed areas of dense
clumping as well as pink/red color, but also displayed greater than usual counter staining with
methylene blue that was not seen in the WT (Figure 30, panel D).
Together, the results demonstrate that targeting of enzymes acting on the side chain
degradation of cholesterol will not lead to production of toxic intermediates and bacteriostatic
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effects, but will instead lead to altered endogenous propionate production and subsequent altered
lipid composition of the cell wall. Mtb is an organism that relies heavily on the production of
virulence lipids on the cell wall, particularly the methyl branched lipids such as mycolic acids,
sulfolipids (SL), di-and-tri-acylated trehaloses (DAT and TAT), poly-acyltrehaloses (PAT) and
phthiocerol dimycocerosates (PDIM) [2]. All of these virulence lipids can be affected by altered
endogenous levels of propionate and altered lipid composition of the cell wall. These results
provide promising avenues for continued investigation of ligase enzymes in this pathway for
development of novel therapeutics capable of targeting the synthesis of many virulence lipids that
could be used to help control the proliferation of drug resistant tuberculosis.
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Appendix

Appendix A. Growth of ΔkstD mutant strains in M. smegmatis with 7H9, 0.2% glycerol
(v/v), 0.5% tyloxapol/acetone (v/v). Growth was carried out for 236 h in 250 mL flasks and was
monitored using a 96 well plate reader. 200-proof ethanol was spiked at 48 h to 0.5% final (v/v)
to evaluate its effect on rescuing growth defect.
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Appendix B. Growth of ΔkstD mutant strains in M. smegmatis with 7H9, 0.2% glycerol
(v/v), 0.5% tyloxapol/acetone (v/v), 1 mM cholest-4-en-3-one. Growth was carried out for 236
h in 250 mL flasks and was monitored using a 96 well plate reader. 200-proof ethanol was spiked
at 48 h to 0.5% final (v/v) to evaluate its effect on rescuing growth defect.
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Appendix C. Quantification of cholest-4-en-3-one of Δkstd mutant strains in M. smegmatis
with 7H9, 0.2% glycerol (v/v), 0.5% tyloxapol/acetone (v/v), 1 mM cholest-4-en-3-one.
Detection was carried out using a CAD, and quantified using calibration curves performed with
cholest-4-en-3-one standards and analyzed using Chromeleon 7 software. Lines indicate grand
mean at each time point across all strains.
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